

RESEARCH ARTICLE

Open Access



Postnatal developmental dynamics of cell type specification genes in Brn3a/Pou4f1 Retinal Ganglion Cells

Vladimir Vladimirovich Muzyka^{1*}, Matthew Brooks² and Tudor Constantin Badea^{1*} 

Abstract

Background: About 20–30 distinct Retinal Ganglion Cell (RGC) types transmit visual information from the retina to the brain. The developmental mechanisms by which RGCs are specified are still largely unknown. Brn3a is a member of the Brn3/Pou4f transcription factor family, which contains key regulators of RGC postmitotic specification. In particular, Brn3a ablation results in the loss of RGCs with small, thick and dense dendritic arbors ('midget-like' RGCs), and morphological changes in other RGC subpopulations. To identify downstream molecular mechanisms underlying Brn3a effects on RGC numbers and morphology, our group recently performed a RNA deep sequencing screen for Brn3a transcriptional targets in mouse RGCs and identified 180 candidate transcripts.

Methods: We now focus on a subset of 28 candidate genes encoding potential cell type determinant proteins. We validate and further define their retinal expression profile at five postnatal developmental time points between birth and adult stage, using in situ hybridization (ISH), RT-PCR and fluorescent immunodetection (IIF).

Results: We find that a majority of candidate genes are enriched in the ganglion cell layer during early stages of postnatal development, but dynamically change their expression profile. We also document transcript-specific expression differences for two example candidates, using RT-PCR and ISH. Brn3a dependency could be confirmed by ISH and IIF only for a fraction of our candidates.

Conclusions: Amongst our candidate Brn3a target genes, a majority demonstrated ganglion cell layer specificity, however only around two thirds showed Brn3a dependency. Some were previously implicated in RGC type specification, while others have known physiological functions in RGCs. Only three genes were found to be consistently regulated by Brn3a throughout postnatal retina development – Mapk10, Tusc5 and Cdh4.

Keywords: Retinal ganglion cell, Subtype specification, Postnatal development, Brn3a, RNA sequencing, in situ hybridization, Dendrite formation, Synapse formation

Background

Retinal ganglion cells (RGCs) are the only neurons in the vertebrate retina which are directly connected to the brain. Mouse RGCs can be subdivided in ~ 30 different types with distinct specific molecular markers, dendritic arbor morphologies, synaptic partners and axonal projections [1–5]. There are several stages of RGC specification during embryonic and postnatal development. Mouse RGCs become postmitotic and start to express

selective molecular markers at embryonic day 11 (E11). RGC axons pass the optic chiasm around E12 and reach the most remote retinorecipient areas of the brain by E15 [6, 7]. Around birth (postnatal day 0, P0) RGC axons invade their target nuclei in the brain, and the first two postnatal weeks are the most intense period for synapse formation. RGC dendrites begin their development later, and the lamination within the inner plexiform layer becomes clearly visible only around P3, grossly develops by P7, and reaches nearly final state after P14 [8, 9]. Mouse eyes open at P13-P14, when synapses between RGCs and bipolar and amacrine cells are already formed, and light-driven synaptic pruning

* Correspondence: vladimir.muzyka@nih.gov; badeatc@mail.nih.gov

¹Retinal Circuit Development & Genetics Unit, Building 6, Room 331B Center Drive, Bethesda, MD 20892–0610, USA

Full list of author information is available at the end of the article



takes place [10]. At P22 RGC axons and dendritic arbors are already “mature”, and cells are completely specified into multiple subtypes [11]. Numerous screens seeking to identify RGC subpopulation specific molecules were performed [12, 13], but we still do not have a comprehensive footprint of RGC diversity in terms of unique molecular signatures.

The Brn3/Pou4f family of transcription factors (TFs) comprising Brn3a, Brn3b and Brn3c is expressed in the retina specifically in RGCs, and its members form a major part of a combinatorial code for RGC type determination [1, 2, 11, 14, 15]. The RGC specification program requires Brn3b and/or Isl1 to initiate, and these TFs are crucial for survival, correct determination of cell fate and axonal targeting of RGCs during development [11, 16–23]. Brn3a starts to be expressed in embryonic retina 1 day later than Brn3b (E12.5 vs. E11.5). It is downstream of Brn3b in the RGC developmental transcriptional cascade, and was initially thought to function redundantly with Brn3b [24, 25]. Brn3a gene ablation is perinatal lethal due to the defects in the somatosensory system and brainstem nuclei, but it does not lead to dramatic perturbations within the retina at this point of development [26, 27]. A reporter knock-in allele expressing alkaline phosphatase (AP) at the Brn3a (*Brn3a^{CKOAP}*) locus was previously used by our group to describe Brn3a cell type distribution among RGCs [2, 11], and also enabled us to identify axonal and dendrite arbor defects in RGCs missing Brn3a either alone or in combination with other Brn3s [28]. Dendrites of Brn3a-expressing RGCs are stratified in the outer laminae (~70%) of the inner plexiform layer (IPL) of the retina. Retina-specific Brn3a loss leads to an elimination of AP-expressing RGC arbors in a thin stripe along the border between ON and OFF layers of the IPL [11]. Retinal Brn3a loss results in a shift towards bistratified RGC dendritic arbor morphologies and overall RGC numbers reduction of around 30–40% depending on retinal region [11, 28], in part by eliminating small RGCs with dense multistratified dendritic morphology [2, 28]. The consequences of Brn3a ablation on RGC subpopulations are obvious already in the early postnatal period (P4) and associated with both cell fate change and cell number loss [11, 28]. However, the molecular mechanisms by which Brn3a controls RGC cell numbers and morphological features are still unclear. To find possible candidates of Brn3a-mediated regulation along with the novel subtype-specific markers, our group has recently performed a RNA deep sequencing screen which defined transcriptomes of Brn3a-positive RGCs and Brn3a-dependent RGC transcripts. The study found transcription factors (TFs), trans-membrane and intracellular structural molecules, that are enriched in RGC subpopulations and selectively depend on Brn3a expression. Overall, 180 transcripts were detected to be potential Brn3a targets at P3 [5].

Molecular determinants of neuronal subtypes can range from expression regulators to final-step effector molecules which provide a basis for cell-cell interactions and neuronal physiology and neuroanatomy [5]. TFs could serve as the most upstream “classifiers” of neuronal types by controlling the expression of identity-specific downstream genes which shape and modulate structural and functional characteristics of a cell [29–31]. Downstream effectors include cell-surface adhesion molecules which are crucial in definition of axon and dendritic morphologies via interaction with their partners on other cells [32–34]. Structural and cytoskeleton-associated molecules provide a mechanistic basis for morphological changes [35–38], and intracellular signaling molecules regulate those processes under transcription factor control [39–43]. Another key part of neuronal identity is provided by pre- and postsynaptic partners within the neuronal circuit. Specialized cell adhesion molecules, neurotransmitter and neurotrophin receptor subunits and other adaptors can confer specificity at both pre- and postsynaptic sites [40, 44–46]. Trophic factors and other secreted molecules are often secreted from postsynaptic sites to attract or repel presynaptic components (axons) and modulate connectivity during synaptogenesis and activity-dependent synaptic remodeling [47]. In addition to this, there are many non-secreted axon-guidance regulating molecules [48].

The goal of the current study is to identify potential Brn3a target molecules that contribute to the development and function of RGCs. Since we are interested in the terminal differentiation process – defining individual cell types – we are focusing on postnatal developmental time points. Specifically, we aim to analyze Brn3a influence on cell type determinants such as transcriptional regulators, adhesion molecules, synaptic elements and intracellular signaling/cytoskeleton apparatus. We used a Rax:Cre driver to produce retina-specific Brn3a ablation and evaluated potential targets previously identified in our P3 RNASeq screen by in situ hybridization (ISH), RT-PCR, and protein immunodetection experiments in postnatal Brn3a KO (Rax:Cre; *Brn3a^{CKOAP/KO}*) and Brn3a WT (Rax:Cre; *Brn3a^{CKOAP/WT}*) retinas. We performed our analysis over a developmental time series in order to correlate the expression dynamics of our target molecules to the postnatal stages of RGC development. We find that RNASeq and ISH data are in good agreement with regard to RGC enrichment and only to some extent to Brn3a regulation of our target genes at P3, but that many of the tested targets exhibit significant changes in expression profile between P0 and P22. For many of our target genes, multiple transcripts are expressed coincidentally in the retina with clearly distinct cell specificity. Finally, predicted intron-exon structures from genome annotation are not always accurate, and novel exon splicing sequences can be detected upon

closer scrutiny. Nevertheless, multiple targets exhibit interesting patterns consistent with expression in one or a few RGC types, and regulation by *Brn3a*.

Methods

Mouse strains and crosses

Mouse lines carrying alleles *Rax:Cre* and *Brn3a^{CKOAP}* were previously described [11, 49]. To obtain Cre-mediated recombination in RGCs, the following cross was set up: *Rax:Cre; Brn3a^{KO/WT}* male x *Brn3a^{CKOAP/CKOAP}* female, to generate two types of progeny: *Rax:Cre; Brn3a^{CKOAP/WT}* and *Rax:Cre; Brn3a^{CKOAP/KO}*. RGCs/retinas of these mice were either *Brn3a* heterozygotes, which are phenotypically wild type (*Brn3a^{AP/WT}*, WT) or *Brn3a* knock-outs (*Brn3a^{AP/KO}*, KO). All mice were on C57/Bl6-SV129 mixed background. All animal procedures were approved by the National Eye Institute (NEI) Animal Care and Use Committee under protocol NEI640.

In situ hybridization (ISH)

ISH experiments were performed on P0, P3, P7, P14 and P22 eyes using an adapted Schaeren-Wiemers protocol [5]. Probes had a length between 160 and 900 bp (Table 1), a melting temperature between 77 °C and 94 °C, and were devoid of low-complexity regions, GC-rich or repetitive sequences. Probes for the main screen (experiments in Figs. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13) were targeted to 3'-UTRs of studied genes. Transcript-specific probes were designed for *Pnkd* and *Clcc1* by targeting probes to unique exons as indicated in Figs. 14 and 15. The specific regions of the mRNA chosen for probes were in the areas highly covered by RNASeq reads, as determined from our data using IgViewer [50]. DNA templates for probes were derived by PCR from mouse genomic ES cell DNA (SV129 strain). All primers are provided in Table 1. A T3 promoter consensus sequence (GGAG CAAATTAACCCTCACTAAAGGG) was added to each reverse primer. Purified PCR products were used as templates for RNA probe synthesis, using T3 polymerase. Quality and concentration of the resulting RNA was assessed by 260/280 spectrometry or micro-electrophoretic analysis on a Bioanalyzer instrument (Thermo Scientific). Eyes for ISH were enucleated, cornea and lens removed, and the resulting eyecups were fixed for 1 h at RT in 4% paraformaldehyde (PFA). For each age, 4–8 eyes including *Brn3a* WT and KO genotypes were embedded in one OCT block, cryoprotected and sectioned at 14 μm thickness. ISH procedure was then performed as recently described [5], with two significant differences: 200 ng of probe were used for each hybridization, and the anti-DIG-AP antibody was used at 1:2000 (Fab fragments; Roche). The colorimetric reaction was developed between 2 and 9 h, individual incubation times for each probe are provided in Table 1.

All images were acquired using the 20× objective of a Zeiss Axio Imager.Z2 at bright-field settings and Axiovision software. For each probe, genotype and age, six or more images derived from 2 to 3 animals were collected.

Quantitation: For each genotype and age 2–3 images were used. From each image for P7-P22 ages we picked 3 areas (ROIs) in each of GCL (ganglion cell layer), IPL (inner plexiform layer), INL (inner nuclear layer) and ONL (outer nuclear layer) and quantitated mean gray value of the pixels. The areas of ROIs from same retina layer were similar. For each measurement, GCL, INL, ONL and IPL ROIs of same length were registered along the section plane. At P3 we were restricted only to 3 layers (GCL, IPL and NBL - neuroblast layer), at P0 – only two – GCL and NBL. For P7-P22 measurements, we subtracted the GCL, the INL and the ONL values from the respective IPL ROI value to acquire normalized values. In case of P3 we subtracted the GCL and the NBL values from the IPL ones. Finally, in case of P0 we were not able to provide IPL normalization because at this age there are no visible IPL. Normalized (P3-P22) and un-normalized (P0) values we then used for representation on the plots.

There are certain limitations to our quantitation method especially in the case of sparsely expressed genes. Even if sparsely located cells have extremely high expression levels, after averaging to the whole area, this could be hidden by the non-expressing or low-expressing majority of cells (for example, in case of *Gabra1* expression in WT GCL at P14).

Reverse transcription – Polymerase chain reaction (RT-PCR)

Total RNA from P3 WT retinas was extracted as previously described. Reverse transcription was performed according to manufacturer's instructions using SuperScript II RT (Invitrogen) and PCR amplification using Taq DNA polymerase (New England Biolabs), using a touch-down protocol. Forward and reverse primers for PCR are shown in Table 1, and primer combinations used for transcript-specific identification are presented in Table 2. PCR products were assessed in 1.5% agarose gel electrophoresis, extracted from gel, eluted in TE buffer, and inserted by T-A cloning into the pGEM-T Easy Vector System (Promega). After transformation, 4 colonies for each inserted PCR product were recovered, and analyzed by restriction digestion. All insert diagnostic digests resulted in DNA fragments of expected length. For each predicted product, identity was confirmed by sequencing plasmid DNA from two of the recovered colonies.

Indirect immunofluorescence (IIF)

For IIF, eyecups were fixed in 2% PFA for 30 min at RT, and cryoprotected in OCT. Slides were blocked (PBS,

Table 1 Primers for ISH probes and RT-PCR

| Gene | Forward Primer Sequence | Reverse Primer Sequence | Product Size, bp | Incubation (P0-P7), h | Incubation (P14-P22), h |
|--------------------------------|-----------------------------|------------------------------|------------------|-----------------------|-------------------------|
| For 3'-UTR probes | | | | | |
| Ankrd13b | TCCAAGGGCGGAGGCAGGT | ATCAGGGAAGGGAAGAGGAAG | 821 + (26) | 5 | 6 |
| Cdh4 | AAGTCCCAGCACTGATGAAAAA | CACCACCCGAATTGTTTGC | 501 + (26) | 6 | 6 |
| Elfn1 | CCTGCGCAAGAAGGTTTCAGTT | CTTGCTTGCTGCACCAGGC | 367 + (26) | 6 | 6 |
| Eml1 | CACTGTGATTTCTGTTTTGTCTA | GCCAGCCTCCCAAAGGGAG | 473 + (26) | 6 | 3 |
| Fam19a4 | AACTTTATGAACCTTGGAG AATG | TGAAATTGGAGGCAAGATG ACT | 498 + (26) | 6 | 3 |
| Foxp2 | CTGTGCTGTTAGTGTAAGATGT | GTTGCTTTCTAGAGTGTCA TAAC | 503 + (26) | 3 | 3 |
| Gabra1 | GTTCTTTTAGTCGTATTCTGTTG | GAGCTTGCAAAATAGATTT GCC | 900 + (26) | 6 | 6 |
| Grm4 | GCCACACAGGCCTTCCTTCC | CTTCGAAACACACTCAAGA TTAG | 433 + (26) | 6 | 5 |
| Hpca | CCTCTCCCTCGTGTCTATCC | GAGCTGGGACAAGAAGTGTTT | 443 + (26) | 6 | 3 |
| Plppr3 | CAGTGCCAGCTCCGACTCTT | TTGCCAGGCTTAGCTCGGTA | 469 + (26) | 6 | 6 |
| Mapk10 | GTCACAACGCACTCACGAAAG | ATCTGTATCTACATCCATC TGAC | 364 + (26) | 6 | 5 |
| Nptx1 | GGGGCTGAGAGCTCACTTG | ACCACTTCGAGCCACGCTC | 600 + (26) | 6 | 5 |
| Nptx2 | TCTCCGTCAGAGGCCAC | CAGTCCCTCAGACGGAAG | 486 + (26) | 6 | 6 |
| Ntrk1 | ATCGAGTGTATCACGCAGGGC | TATGATGGATGCTGGCCAT GAA | 328 + (26) | 6 | 5 |
| Pcdh20 | GACGAGTTTCTACTTCTTGGG | TTATCGTTGATGTCCAGAA GAAG | 511 + (26) | 6 | 9 |
| Pick1 | ACCACTGTAGGACAGCGAAGG | TTATTCAATACAGGCCAG CTTC | 393 + (26) | 6 | 9 |
| Pip5k1 | ACAAGGTGTGTCGAAGTCGAAG | TAAGGGTTGGGTCAGGGTC | 458 + (26) | 6 | 6 |
| Pnkd | CTTCACCATCCTTTCATCACT | GAAGGTGGAAGATAGACTA GCC | 360 + (26) | 6 | 6 |
| Rims1 | CACCCTCCTCTGGAGTCCAG | TGTGTCTGCAGTTTATACC AATG | 500 + (26) | 2 | 3 |
| Tmem25 | TGCCTGTCCCTGTTGTGACC | GTACAAAACGATGCAGAGC TAC | 687 + (26) | 6 | 6 |
| Tmem91 | CAACAAGGCTTGGGCCAAGG | GGGTATCTTTAATTTCTCA CATTG | 348 + (26) | 6 | 5 |
| Tshz2 | GCAGAAAGAAAGGGAAATA TGTG | CATCACCTATTTGTTCTCTTCG | 418 + (26) | 6 | 6 |
| Tusc5 | CTGGAGATCTCCGAACCTACAT | ATGGAGGATTTCCGTATGGCC | 492 + (26) | 6 | 5 |
| Pou4f1 (control) | TGTGTAGAAGATCCCTTTGG | GCACAGAAATGTTCTGATG | 519 + (26) | 3 | 3 |
| For transcript-specific probes | | | | | |
| Clcc1 (pr.1 + pr.9) ^ | CACAGCTGCGGGCCGAGC | CTGAGATTTCTCATCGTTCCT | 208 + (26) | | |
| Clcc1 (pr.2 + pr.9) | AGTCCGCTCGGACTCCAG | CTGAGATTTCTCATCGTTCCT | 181/252 + (26) | 7 | 7 |
| Clcc1 (pr.3 + pr.9) ^ | TGTTTGAGGTAGGCGGCTCG | CTGAGATTTCTCATCGTTCCT | 220 + (26) | | |
| Clcc1 (pr.4 + pr.9) ^ | TCGGCGTCTTCGGCGGCC | CTGAGATTTCTCATCGTTCCT | 203 + (26) | | |
| Clcc1 (pr.5 + pr.9) ^ | TCCCTCTGAAAGAGCAGGCAG | CTGAGATTTCTCATCGTTCCT | 172 + (26) | | |

Table 1 Primers for ISH probes and RT-PCR (Continued)

| Gene | Forward Primer Sequence | Reverse Primer Sequence | Product Size, bp | Incubation (P0-P7), h | Incubation (P14-P22), h |
|---------------------------|-------------------------|-----------------------------|------------------|-----------------------|-------------------------|
| Clcc1 (pr.6 + pr.9) ^* | TGAGTGGGCGCTCTTCGGTG | CTGAGATTTCCTCATCGTTCCT | 293 + (26) | | |
| Clcc1 (pr.7 + pr.9) ^ | CGTTCCAGGATACACCGAGA | CTGAGATTTCCTCATCGTTCCT | 300 + (26) | | |
| Clcc1 (pr.2 + pr.8) ^* | AGTCCGCTCGGGACTCCAG | CGGGTTAAGGGAAGTCAAA TTC | 199/270 + (26) | | |
| Clcc1(pr.7 + pr.8) ^^ | CGTTCCAGGATACACCGAGA | CGGGTTAAGGGAAGTCAAA TTC | 159 + (26) | 4 | 3 |
| Clcc1(pr.10 + pr.11) ^ | GTGAGGTCTGGAACATCAGAG | CATAAACACATTATATGGA TCTA | 432 + (26) | | |
| Pnkd (pr.1 + pr.2) | TGGGACCCGAACATGGCGG | GGTAGCCCCACGGCTTTC | 246 (+ 26) | 2 | 3 |
| Pnkd (pr.3 + pr.4) * | TGTGGTATCCTCTTCTCGTC | CTCCTCCACGGTGTGGAAG | 289 + (26) | 2 | 3 |
| Pnkd (pr.5 + pr.6) | CCCAGCATGGCTTGGCAGG | CCGATTCGGAAGAGCAGCCG | 167 (+ 26) | 2 | 3 |
| Pnkd (pr.5 + pr.7) ^ | CCCAGCATGGCTTGGCAGG | ATTGAAGAGGCGGGGCTGAG | 282 (+ 26) | | |

Left column represents gene name, or gene name together with primer combination for transcript-specific probes. Second and third columns show primer sequences, fourth column shows product length, fifth and sixth columns represent ISH probe incubation times for P0-P7 and P14-P22 retinas. Some of the primer combinations could give rise to two different DNA fragments depending on splice variants. ^ - primer combination used for RT-PCR not ISH. ^^ - primer combination used for ISH not RT-PCR. * - primer combination gave negative result in RT-PCR. Primer combinations pr.3 + pr.8, pr.4 + pr.8, pr.6 + pr.8 for Clcc1 not shown in this table also gave negative results (for predicted fragment sizes see Table 2). Numbers in parenthesis refer to T3 promoter extension, as required for ISH probe generation

Table 2 Predicted and confirmed splicing variants for Clcc1 and Pnkd

| Primer Pair | fragment size, bp | Predicted transcripts | Confirmed splice junctions |
|---------------|-----------------------|---|----------------------------|
| Clcc1 | | | |
| pr.1 + pr.9 | 208 + (26) | NM_145543^ | ex.1a_ex.3 |
| pr.2 + pr.9 | 181+ (26), 252 + (26) | NM_145543^, NM_001177771, XM_006501416^, XM_011240107 | ex.1a/1b_ex.3 |
| pr.3 + pr.9 | 220 + (26) | NM_001177771, XM_006501416^, XM_011240107 | ex.1b_ex.3 |
| pr.4 + pr.9 | 203 + (26) | NM_001177771, NM_001177770, XM_006501416^, XM_011240107 | ex.1b_ex.3 |
| pr.5 + pr.9 | 172 + (26) | NM_001177771, NM_001177770, XM_006501416^, XM_011240107 | ex.1b_ex.3 |
| pr.6 + pr.9* | 293 + (26) | NM_001177770, XM_011240107 | none |
| pr.7 + pr.9 | 300 + (26) | NM_001177771, novel uncharacterized | ex.2_ex.3 |
| pr.2 + pr.8* | 199 + (26) 270 + (26) | NM_001177771 | none |
| pr.3 + pr.8* | 238 + (26) | NM_001177771 | none |
| pr.4 + pr.8* | 221 + (26) | NM_001177771 | none |
| pr.6 + pr.8* | 453 + (26) | none | none |
| pr.7 + pr.8 | 159 + (26) | NM_001177771, novel uncharacterized | ex.2 |
| pr.10 + pr.11 | 432 + (26) | all transcripts | ex.4_ex.5_ex.6 |
| Pnkd | | | |
| pr.1 + pr.2 | 246 + (26) | NM_025580, NM_001039509^ | ex.2_ex.3 |
| pr.3 + pr.4* | 289 + (26) | NM_025580 | none |
| pr.5 + pr.6 | 167 + (26) | NM_019999^ | ex.5 |
| pr.5 + pr.7 | 282 + (26) | NM_019999^ | ex.5_ex.6 |
| pr.8 + pr.9 | 360 + (26) | all transcripts | 3'-UTR |

Column 1 represents primer combinations, column 2 – DNA fragment size after RT-PCR. Some of the primer combinations could give rise to two different DNA fragments from two different splice variants. Column 3 shows transcript variants predicted to be recognized by the respective primer combination. Column 4 demonstrates exon-to-exon splicing junction which were experimentally confirmed by RT-PCR using respective primer combination. ^ - transcripts detected by RT-PCR. * - primer combination which gave negative result in RT-PCR. Numbers in parenthesis refer to T3 promoter extension, as required for ISH probe generation (Table should appear after "Clcc1 transcripts detected in the retina" section in "Results")

10% bovine serum albumin (BSA), 10% normal donkey serum (NDS) and 0.5% Triton) for 1 h at RT and incubated at 4 °C overnight in primary antibody mixes (PBS, 10% BSA, 3% NDS, 0.5% Triton, and primary antibodies). Antibodies used were 1:100 rat anti-Cdh4 (MRCD5, provided by M. Takeichi and H. Matsunami to DSHB; dshb.biology.uiowa.edu; [51]), 1:200 rabbit anti-Elfn1 (gift from Dr. K. Martemyanov, The Scripps Research Institute, Jupiter, USA), 1:200 sheep anti-AP (American Research products, 13–2355), 1:20 mouse anti-Brn3a (MAB1585; Chemicon-Millipore). After washes, secondary antibody solutions were applied for 1 h RT (150 µl per slide - PBS, 10% BSA, 3% NDS, 0.5% Triton, 0.5 µl of 1000× DAPI and secondary antibodies). All secondaries were Alexa conjugated Donkey sera from Molecular Probes. Images were captured with a 40× lens on a Zeiss Imager.Z2 fitted with an Apotome for fluorescent imaging and Axiovision software. For each probe, genotype and age, eight or more images derived from at least 3 animals were collected.

Statistical analysis

We used Kolmogorov-Smirnov (KS2) test for statistical assessment of ISH quantitation results. Sample numbers, means, medians and significance levels for KS2 and student t tests are provided in Additional file 1: Table S1.

Results

Screening strategy

To identify genes that could be responsible for RGC type specification in Brn3a-knockout retinas, we performed an in situ hybridization screen using a set of potential Brn3a-specific target genes recently identified in our RGC-specific RNASeq screening [5].

In order to achieve complete ablation of *Brn3a* from RGCs, we crossed females homozygote for the previously reported *Brn3a*^{CKOAP/CKOAP} allele [9] with Rax:Cre; *Brn3a*^{KO/WT} males. Rax:Cre is a BAC transgenic allele [49] that provides essentially complete Cre recombination beginning at early stages of eye development (Embryonic day 9, E9). Offspring were either Rax:Cre; *Brn3a*^{CKOAP/WT} resulting in Brn3a heterozygote RGCs (henceforth Brn3a^{AP/WT} RGCs) or Rax:Cre; *Brn3a*^{CKOAP/KO} resulting in Brn3a knockout RGCs (henceforth Brn3a^{AP/KO} RGCs). As previously reported, Brn3a protein is expressed in a large fraction of Ganglion Cell Layer (GCL) nuclei, and dendrites of Brn3a^{AP/WT} RGCs occupy the outer two-thirds of the Inner Plexiform Layer (IPL, Fig. 1a, c). However, in Rax:Cre; *Brn3a*^{CKOAP/KO} retinas there are essentially no Brn3a positive cells, and the dendrites of Brn3a^{AP/KO} RGCs show a gap in AP-positive lamination (Fig. 1b, d). This gap, which extends between the characteristic positions of Choline-Acetyl-Transferase (ChAT) positive Starburst

Amacrine cells, is largely due to loss of RGCs with small and dense dendritic arbor (midget-like cells) (Fig. 1b, d) [2, 9, 28]. In order to capture the essential events in RGC type specification (dendrite formation, axon invasion into retinorecipient nuclei, synaptogenesis, and functional maturation) we prepared retinal sections from Rax:Cre; *Brn3a*^{CKOAP/KO} and Rax:Cre; *Brn3a*^{CKOAP/WT} littermate controls at five postnatal ages – P0, P3, P7, P14 and P22.

The genes screened in this study represent a subset of potential Brn3a target genes identified by comparing transcript level RNASeq data from Brn3a^{AP/KO} and Brn3a^{AP/WT} postnatal day 3 RGCs [5]. Genes selected in our ISH analysis had to have at least one transcript with more than 2 FPKM (fragments per million reads per gene kilobase) expression level in RGCs, and at least a two-fold differential in Brn3a^{AP/WT} versus Brn3a^{AP/KO} RGCs (Brn3a regulated or dependent). In addition, the Brn3a dependent transcript should show no Brn3b regulation (less than two-fold differential in P3 Brn3b^{AP/WT} versus Brn3b^{AP/KO} RGCs). From the set of 180 differentially expressed transcripts that had these criteria (identified in [5]), we focused on genes whose products had potential functional association with gene regulation, synapse formation, cell adhesion, vesicle transport, cytoskeleton changes, intracellular signaling, or secreted molecules. These molecular classes should be particularly important during RGC type specification.

In Figs. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13, we provide RNASeq data for transcript and gene expression and ISH results together with its quantitation for all target genes, organized by molecular class. ISH quantitation results are summarized in Additional file 1: Table S1. RNASeq data for transcript expression are derived from the Sajgo et al. [5] data set and gene level analysis is based on the same dataset (however it takes into account all possible transcript isoforms, not only RefSeq ones). RNASeq data for transcript expression represent all RefSeq transcripts that had at least 1 FPKM expression level in at least one retinal or RGC sample and including the ones that passed the above selection criteria. Note that the x scales for each plot are different, depending on the range of FPKM/CPM (counts per million reads) values in the individual samples. The ISH panels show the gene level analysis, with riboprobes directed against the 3'-Untranslated Regions (3'-UTR), which are shared by all transcripts.

Transcriptional and translational regulators (Figures 2 and 3)

Two transcription factors (Foxp2 and Tshz2) and one RNA processing factor (Rbfox1) passed our selection criteria. Two Rbfox1 (RNA binding protein, fox-1 homolog 1) RefSeq transcripts were significantly expressed in P3 Brn3a⁺ RGCs compared to the retina (NM_021477 and




Fig. 1 Retinal Brn3a ablation results in specific RGC defects. **a-b** Summary of Brn3a RGC phenotype, based on previous work [2, 9, 28]. Distribution of dendritic arbors for Brn3a heterozygote (**a**, Brn3a^{AP/WT}) and Brn3a knock-out (**b**, Brn3a^{AP/KO}) RGCs. **a** Dendrites of Brn3a^{AP/WT} RGCs, including ON-OFF-DS bistratified (left) and midget-like (right) cells, occupy the outer two-thirds of the Inner Plexiform Layer (IPL, gray). **b** Midget-like cells are absent from Brn3a^{AP/KO} RGCs, and the dendrites of remaining cells are co-stratifying with the inner and outer Starburst Amacrine cell dendritic arbors (blue lines). **c-d** Indirect immunofluorescence illustrating Brn3a^{AP} RGC arbors and cell bodies (red), and Brn3a transcription factor expression (green) in Rax:Cre; Brn3a^{CKOAP/WT} (**c**) and Rax:Cre; Brn3a^{CKOAP/KO} (**d**) adult retinas. Note the gap of Brn3a^{AP} staining in **d**, and the absence of Brn3a TF positive cell bodies in the GCL. ONL = Outer Nuclear Layer; OPL = Outer Plexiform Layer; INL = Inner Nuclear Layer; IPL = Inner Plexiform Layer; GCL = Ganglion Cell Layer. Red bars in IPL of (**d**) indicate the position of inner and outer ChAT bands. Arrowheads are showing AP-expressing cells. Scale bar in D, 25 μm

NM_183188, Fig. 3a^{II}-a^{III}), but only NM_021477 showed significant Brn3a dependence. Gene level RNASeq analysis for Rbfox1 also revealed both RGC-enrichment as well as tendency towards Brn3a-mediated regulation of expression (Fig. 3a^I). The in situ time series (Fig. 2a) confirmed relative GCL enrichment for Rbfox1 from P0-P7 (P0 WT and KO – $p < 0.001$; P3 KO, P7 WT and KO – $p < 0.05$, Additional file 1: Table S1 A-C), however beginning with P7, the INL and eventually the ONL turned positive (Figs. 2a, 3a). Differential expression between Brn3a^{WT} and KO retinas was not observed. Both Foxp2 (forkhead box P2) transcripts expressed in the retina (NM_212435 and NM_053242) were selectively enriched in Brn3a RGCs and appeared regulated by Brn3a (Fig. 3b^{II}-b^{III}). Gene level RNASeq analysis also showed strong differential expression in Brn3a WT RGCs compared to Brn3a KO RGCs. Enrichment of Foxp2 expression in the GCL was confirmed by ISH in early time-points (P0-P3) and in the adult, while the significant ($p < 0.001$) regulation by Brn3a in the GCL

was observed at P7 and P22 (Figs. 2b, 3b, Additional file 1: Table S1). Tshz2 (teashirt zinc finger homeobox 2) showed enrichment in RGCs vs. retina as well as Brn3a dependency at both gene and transcript level (Fig. 3c^I-c^{II}). ISH confirms modest but significant GCL enrichment from P0-P14 and Brn3a regulation at P3 ($p < 0.05$) and P22 ($p < 0.001$, Figs. 2c, 3c, Additional file 1: Table S1). Note that Brn3a signal can still be detected in the GCL of Rax:Cre; Brn3a^{CKOAP/KO} (KO) retinas (Fig. 2d), since the ISH probe is directed against the 3'UTR region which is not ablated in the recombined conditional knock-in allele (Brn3a^{AP}) and Brn3a ablation results in only 30–40% reduction in total Brn3a⁺ RGC numbers [5, 9, 28].

Intracellular signaling and cytoskeleton-associated proteins (Figures 4 and 5)

Eml1 (echinoderm microtubule associated protein like 1) has 3 transcripts (NM_001286347, NM_001043335 and NM_001286346, Fig. 5a^{II}-a^{IV}), and only one of them (NM_001286347) shows Brn3a RGC enrichment and




Fig. 2 Candidate Brn3a target genes: Transcriptional and Translational regulators. In situ hybridization profiles for potential Brn3a target genes. Retinal sections from *Rax:Cre; Brn3a^{CKOAP/WT}* (left panel, WT) and *Rax:Cre; Brn3a^{CKOAP/KO}* (right panel, KO) mice, harvested at Postnatal days 0, 3, 7, 14 and 22 (P0, P3, P7, P14 and P22). The in situ hybridization probes were generated against the 3'-UTR of the corresponding target gene, using primers indicated in Table 1. A positive control (**d**, Brn3a) and a negative control (**e**, no probe) are shown. Bars on the right represent retina layers positions: black – NBL (neuroblast layer), red – GCL, cyan – IPL, blue – ONL, green – INL. **a** Rbfox1, **b** Foxp2, **c** Tshz2. Scale bar in (**e**), 50 μ m

Brn3a dependence. Gene level analysis shows even distribution of expression between RGC and retina samples at P3 (Fig. 5a^I). ISH (Fig. 4a) demonstrates that *Eml1* is significantly GCL enriched in both WT and Brn3a KO from P0-P7, however beginning with P14, the INL and later the ONL become positive (Fig. 5a, Additional file 1: Table S1). *Eml1* is not differentially expressed between Brn3a WT and KO retinas throughout studied postnatal developmental period. *Hpca* (hippocalcin) has 4 transcripts expressed in the retina (NM_001130419, NM_010471, NM_001286081 and NM_001286083). First three of them were highly expressed in P3 Brn3a^{AP} RGCs compared to the retina (Fig. 5b^{II-b^{IV}}), while NM_001286083 (Fig. 5b^V) was selectively enriched in Brn3a^{KO} retina. Only NM_001130419 appeared regulated by Brn3a (Fig. 5b^{II}). Gene level analysis revealed enrichment in both Brn3a^{WT} and Brn3a^{KO} RGCs (Fig. 5b^I). Strong and significant GCL enrichment was

confirmed by ISH from P0-P7, however beginning with P14 *Hpca* is highly expressed in both GCL and inner INL. A modest reduction in *Hpca* level is apparent in the GCL of Brn3a^{KO} retinas at P0 ($p < 0.01$), P14 ($p < 0.01$) and P22 ($p < 0.05$, Figs. 4b, 5b, Additional file 1: Table S1). The only expressed *Plppr3* (phospholipid phosphatase related 3) transcript shows a moderate enrichment in P3 RGCs vs. retina (Fig. 5c^{II}), while RNASeq gene level analysis does not reveal any strong signs of GCL enrichment or Brn3a dependency (Fig. 5c^I). ISH time series confirms the transcript RNASeq results in terms of GCL enrichment from P0-P14 (Figs. 4c, 5c, Additional file 1: Table S1 A-D). The expression of *Plppr3* decreases towards adult and this gene is not affected by Brn3a loss at P0-P7, while at P14 we found significant differential expression between Brn3a WT and KO ($p < 0.01$, Fig. 5c, Additional file 1: Table S1 A-D). Both *Mapk10* (mitogen-activated protein




Fig. 3 (See legend on next page.)

(See figure on previous page.)

Fig. 3 Candidate Brn3a target genes: Transcriptional and Translational regulators. RNASeq and ISH quantitation. In situ hybridization quantitation (**a-c**), and gene (*d-c*) and transcript (*d'-c'*) level RNASeq profiles for potential Brn3a target genes. **a-c** Box-whiskers plots for NBL and GCL of P0 and P3, and ONL, INL and GCL for P7-P22 retinas from Rax:Cre; *Brn3a*^{CKOAP/WT} (left panel, WT) and Rax:Cre; *Brn3a*^{CKOAP/KO} (right panel, KO) mice, harvested at P0, P3, P7, P14 and P22 show normalized (all except P0) mean intensity values from images of retinal sections (Y axis). Individual values for each layer are normalized to the respective IPL value in P3-P22 cases. X axis represents retinal layers: N – NBL, G – GCL, O – ONL, I – INL. Horizontal bars in panels denote observation pairs showing significant expression differences (Kolmogorov-Smirnov - KS2 test) between INL/NBL and GCL (black bar) and Brn3a-dependency by comparing respective WT and KO GCL values (green bar; significance levels * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). All values and KS2 test outcomes are provided in Additional file 1: Table S1. *d'-c'* Gene level RNASeq profiles from affinity purified Brn3^{AP} RGCs (RGC) and retinal supernatants (Retina) derived from P3 mice with the following genotypes: Pax6a:Cre; *Brn3a*^{CKOAP/WT} (Brn3a-WT), Pax6a:Cre; *Brn3a*^{CKOAP/KO} (Brn3a-KO), Pax6a:Cre; *Brn3b*^{CKOAP/WT} (Brn3b-WT), and Pax6a:Cre; *Brn3b*^{CKOAP/KO} (Brn3b-KO) (Sajjo et al. 2017). Values on the x axis are in CPM (counts per million reads), and bars represent mean values for two replicates (RGC samples) and single samples (retina supernatants). *d'-c'* Transcript level RNASeq profiles from the same samples as in *d-c*. Values on the x axis are in FPKM, and bars represent mean values for two replicates (RGC samples) and single samples (retina supernatants). For each gene, only transcripts having detectable (> 1 FPKM values) in at least one of the samples are presented. The transcript (NM) number is indicated under the gene name. *d'-a''* Rbfox1, *b'-b''* Foxp2, *c'-c''* Tshz2




Fig. 4 Candidate Brn3a target genes: Intracellular signaling and cytoskeleton-associated proteins. **a-e** In situ hybridization analysis in WT and Brn3a-KO mouse retinas at 5 postnatal ages. **a** Eml1, **b** Hpca, **c** Plppr3, **d** Mapk10, **e** Pip5k11. All samples were collected, imaged and formatted as in Fig. 2. Scale bar – 50 μ m




Fig. 5 (See legend on next page.)

(See figure on previous page.)

Fig. 5 Candidate Brn3a target genes: Intracellular signaling and cytoskeleton-associated proteins. RNASeq and ISH quantitation. **a-e** In situ hybridization quantitation analysis in WT and Brn3a-KO mouse retinas at 5 postnatal ages. *d^I-e^I* RNASeq gene level profiles at P3 (expressed in CPM). *d^{II}-e^{II}* RNASeq transcript level profiles expressed in FPKM for all transcripts of the five genes detected at more than 1 FPKM in at least one P3 retinal sample. *a-d^{IV}* Eml1, *b-b^V* Hpcra, *c-c^{II}* Plppr3, *d-d^{III}* Mapk10, *e-e^{II}* Pip5kl1. Plot formatting and annotations as in Fig. 3

kinase 10) isoforms (NM_001081567 and NM_009158, Fig. 5d^{II}-d^{III}) are enriched in RGCs compared to the retina. Only one of them (NM_001081567) appears to be regulated by Brn3a (and also Brn3b) at P3. Gene level analysis confirms only enrichment in Brn3a WT and KO samples, and differential expression between Brn3b WT and KO (Fig. 5d^I). ISH reveals significant Mapk10 GCL enrichment throughout postnatal development (P0-P22, Figs. 4d, 5d, Additional file 1: Table S1). Beginning with P7, Mapk10⁺ cell bodies sparsely label the GCL, and their number appears to be reduced in Brn3a^{KO} retinas compared to the WT at the majority of studied ages (P0 *p* < 0.05, P7 *p* < 0.05, P14 *p* < 0.01, P22 *p* < 0.001, Additional file 1: Table

S1). Transcript and gene RNASeq profiles show enrichment, and in case of a transcript – Brn3a dependency of Pip5kl1 (phosphatidylinositol-4-phosphate 5-kinase like 1) expression in P3 RGCs vs. retina (Fig. 3e^I-e^{II}). However, in situ time series confirms GCL enrichment only at P7 (*p* < 0.05) and P14 (*p* < 0.01), and it does not reveal a considerable Brn3a regulation of Pip5kl1 (Figs. 4e, 5e, Additional file 1: Table S1).

Vesicle-associated proteins (Figures 6 and 7)

Transcript level RNASeq shows that the only expressed Ankrd13b (ankyrin repeat domain 13b) RefSeq transcript is strongly enriched in Brn3a^{AP/WT} RGCs compared to




Fig. 6 Candidate Brn3a target genes: Vesicle-associated proteins. **a-d** In situ hybridization analysis in WT and Brn3a-KO mouse retinas at 5 postnatal ages. **a** Ankrd13b, **b** Pick1, **c** Snap91, **d** Tusc5. All samples were collected, imaged and formatted as in Fig. 2. Scale bar – 50 μm




Fig. 7 (See legend on next page.)

(See figure on previous page.)

Fig. 7 Candidate Brn3a target genes: Vesicle-associated proteins. RNASeq and ISH quantitation. **a-d** In situ hybridization quantitation analysis in WT and Brn3a-KO mouse retinas at 5 postnatal ages. **d-d'** RNASeq gene level profiles at P3 (expressed in CPM). **a''-d''** RNASeq transcript level profiles expressed in FPKM for all transcripts of the four genes detected at more than 1 FPKM in at least one P3 retinal sample. **a-a''** Ankrd13b, **b-b''** Pick1, **c-c''** Snap91, **d-d''** Tusc5. Plot formatting and annotations as in Fig. 3

the retina and other RGC samples (Fig. 7a^{II}). At the same time, gene level analysis revealed only the enrichment in Brn3a WT and KO samples but not the dependency on Brn3a (Fig. 7a^I). ISH confirms strong enrichment in the GCL from P0-P7, which decreases towards adult (Fig. 7a). There is no significant Brn3a regulation in the GCL at any of the studied ages (Additional file 1: Table S1). Two Pick1 (protein interacting with C kinase 1) transcripts (NM_001045558 and NM_008837, Fig. 7b^I-b^{III}) demonstrated a modest enrichment in RGCs vs. retina at P3, while gene expression RNASeq analysis did not show any signs of it (Fig. 7b^I). One of the transcripts (NM_001045558) was enriched in Brn3a^{AP/WT} and Brn3b^{AP/KO} RGCs, suggesting positive regulation by Brn3a and negative regulation by Brn3b (Fig. 7b^{II}). ISH confirms GCL enrichment from P0-P3, however it does not show a significant Brn3a-dependent differential expression (Figs. 6b and 7b, Additional file 1:

Table S1). Snap91 (synaptosome associated protein 91) gene has 4 retinally expressed isoforms (NM_001277985, NM_013669, NM_001277982 and NM_001277983, Fig. 7c^I-c^V), all of which showed enrichment in RGCs compared to the retina. However only NM_001277985 shows a strong dependency on Brn3a expression in RGCs (Fig. 7c^{II}). Gene level analysis confirms RGC enrichment, especially in Brn3a RGC samples, but it does not show Brn3a-dependent differential expression (Fig. 7c^I). ISH time series confirms a significant enrichment in the GCL from P0-P14, and shows the only time point (P3) with significant ($p < 0.05$) Brn3a dependency of expression (Figs. 6c, 7c, Additional file 1: Table S1). According to P3 RNA-Seq data (Fig. 7d^I-d^{III}), Tusc5 (tumor suppressor candidate 5) is highly enriched in Brn3a^{AP/WT} RGCs, compared to the retina and other RGC samples, and strongly regulated by Brn3a. ISH reveals intensely stained sparse cell bodies in the GCL of Brn3a WT retinas, which are nearly completely




Fig. 8 Candidate Brn3a target genes: Synapse-associated proteins. **a-f** In situ hybridization analysis in WT and Brn3a-KO mouse retinas at 5 postnatal ages. **a** Elnf1, **b** Gabra1, **c** Grm4, **d** Ntrk1, **e** Pnkd, **f** Rims1. All samples were collected, imaged and formatted as in Fig. 2. Scale bar – 50 μ m




Fig. 9 (See legend on next page.)

(See figure on previous page.)

Fig. 9 Candidate Brn3a target genes: Synapse-associated proteins. RNASeq and ISH quantitation. **a-f** In situ hybridization quantitation analysis in WT and Brn3a-KO mouse retinas at 5 postnatal ages. *d^{l-f}* RNASeq gene level profiles at P3 (expressed in CPM). *d^{l-f}* RNASeq transcript level profiles expressed in FPKM for all transcripts of the six genes detected at more than 1 FPKM in at least one P3 retinal sample. *a-d^l* Elnf1, *b-b^l* Gabra1, *c-c^l* Grm4, *d-d^l* Ntrk1, *e-e^l* Pnkd, *f-f^l* Rims1. Plot formatting and annotations as in Fig. 3

lost in Brn3a^{KO} (Fig. 6d). ISH quantitation results confirm strong GCL enrichment in the Brn3a WT retinas, and almost absolute dependency of GCL expression on Brn3a (Fig. 7d, Additional file 1: Table S1).

Synapse-associated proteins (Figures 8 and 9)

A single expressed Elnf1 (leucine rich repeat and fibronectin type III, extracellular 1) transcript is expressed in both retina and RGCs, and RNASeq demonstrated its profound differential between Brn3a^{AP/WT} and Brn3a^{AP/^{KO}} RGCs (Fig. 9a^{II}), and gene level analysis confirms this result (Fig. 9a^I). ISH reveals intense sparse labelling in the GCL beginning with P3, peaking around P7 but

persisting in the adult (Fig. 8a). Due to the sparseness of expression the quantitation does not allow to capture significant GCL enrichment (Fig. 9a, Additional file 1: Table S1). Starting at P14, Elnf1 expression can also be seen in the INL and ONL. Beginning with P7, the number of intensely labelled GCL cell bodies declines in the Brn3a KO retinas (Fig. 8a), and this reduction reaches significant levels at P14 ($p < 0.001$) and persists in adult stage ($p < 0.05$, Fig. 9a, Additional file 1: Table S1 D-E). Surprisingly, due to downregulation in Brn3a KO GCL, we also can see a significant enrichment of expression in the INL compared to the GCL at P14 ($p < 0.001$) and adult age ($p < 0.05$). Gabra1 (gamma-aminobutyric acid




Fig. 10 Candidate Brn3a target genes: Secreted proteins. **a-d** In situ hybridization analysis in WT and Brn3a-KO mouse retinas at 5 postnatal ages. **a** – Fam19a4, **b** – Nptx1, **c** – Nptx2, **d** – Sez6l2. All samples were collected, imaged and formatted as in Fig. 2. Scale bar – 50 μ m




Fig. 11 (See legend on next page.)

(See figure on previous page.)

Fig. 11 Candidate Brn3a target genes: Secreted proteins. RNASeq and ISH quantitation. **a-c** In situ hybridization quantitation analysis in WT and Brn3a-KO mouse retinas at 5 postnatal ages. **d-d'** RNASeq gene level profiles at P3 (expressed in CPM). **d'-d''** RNASeq transcript level profiles expressed in FPKM for all transcripts of the four genes detected at more than 1 FPKM in at least one P3 retinal sample. **a-d''** Nptx1, **b-b''** Nptx2, **c-c''** Sez6l2, **d'-d''** Fam19a4. Plot formatting and annotations as in Fig. 3.

A receptor) has one transcript that is enriched in Brn3a^{AP/WT} RGCs compared to the retina and downregulated in Brn3a^{AP/KO} RGCs (Fig. 9b^{II}), which is confirmed by gene level RNASeq analysis (Fig. 9b^I). ISH reveals the start of the expression at P3 in the GCL and P7 in the INL with progressive increase of the signal towards P14 and P22 (Fig. 8b). There are sparse intensely labelled cells in both INL and GCL of P14 and P22 Brn3a WT retina. And due to the sparseness of expression in the GCL but not as much in the INL, the INL levels are significantly higher compared to GCL level in both Brn3a WT and KO at P14 and P22 (Fig. 9b, Additional file 1: Table S1 D-E). Moreover, P22 Brn3a

KO retinas lack positive signal in the GCL but not the INL, suggesting a strong Brn3a dependency of Gabra1 in RGCs but not INL cells (likely Bipolar and/or Amacrine cells). Both transcript and gene level RNASeq analysis suggests that Grm4 (glutamate metabotropic receptor 4) – is enriched in Brn3a^{AP/WT} RGCs and regulated by Brn3a (Fig. 9c^{I-c^{II}}). ISH reveals Grm4 expression in both GCL and INL (NBL) beginning with P0-P7 and continuing towards adult with no visible downregulation in Brn3a KO retinas (Fig. 8c). ISH quantitation shows a significant level of GCL enrichment at P3 (WT $p < 0.05$, KO < 0.01), which later reverts into INL enrichment (P14 WT $p < 0.05$, KO < 0.001 , Fig. 9c). ISH results




Fig. 12 Candidate Brn3a target genes: Adhesion molecules and other transmembrane proteins. **a-e** In situ hybridization analysis in WT and Brn3a-KO mouse retinas at 5 postnatal ages. **a** Cdh4, **b** Pcdh20, **c** Rtn4rl2, **d** Tmem25, **e** Tmem91. All samples were collected, imaged and formatted as in Fig. 2. Scale bar – 50 μ m.





Fig. 13 (See legend on next page.)

(See figure on previous page.)

Fig. 13 Candidate Brn3a target genes: Adhesion molecules and other transmembrane proteins. RNASeq and ISH quantitation. **a-e** In situ hybridization quantitation analysis in WT and Brn3a-KO mouse retinas at 5 postnatal ages. *d^l-e^l* RNASeq gene level profiles at P3 (expressed in CPM). *d^l-e^l* RNASeq transcript level profiles expressed in FPKM for all transcripts of the five genes detected at more than 1 FPKM in at least one P3 retinal sample. *a-d^l* *Cdh4*, *b-b^l* *Pcdh20*, *c-c^l* *Rtn4rl2*, *d-d^l* *Tmem25*, *e-e^l* *Tmem91*. Plot formatting and annotations as in Fig. 3

do not support dependency of *Grm4* expression on *Brn3a* (Additional file 1: Table S1). *Ntrk1* (neurotrophic tyrosine kinase, receptor, type 1) is expressed both in retina and RGCs and differentially regulated by *Brn3a* (Fig. 9*d^l-d^{ll}*). ISH confirms significant *Ntrk1* GCL enrichment at P0 and P3 (Figs. 8*d*, 9*d*, Additional file 1: Table S1 A-B). The INL expression starts at P3, catches up with the GCL at P7-P14, and they both proceed into adult age. *Ntrk1* is expressed exceptionally highly at P14 and P22, however no differential between *Brn3a* WT and KO retinas is apparent at any age (Figs. 8*d*, 9*d*, Additional file 1: Table S1). *Pnkd* (paroxysmal non-kinesigenic dyskinesia) has three RefSeq isoforms (NM_019999, NM_025580 and NM_001039509, Fig. 9*e^{ll}-e^{lv}*), all of them seem to be

expressed in both RGCs and retina, but only one of them is regulated by *Brn3a* (NM_019999, Fig. 9*e^{ll}*). Gene level analysis demonstrates broad expression in both RGCs and retina with no apparent regulation by *Brn3a* (Fig. 9*e^l*). The 3'-UTR in situ probe common for all 3 isoforms allows to find *Pnkd* expression in the GCL and other retinal layers beginning with P0-P3 (Fig. 8*e*). We find significant enrichment of *Pnkd* expression in the GCL of *Brn3a* WT retinas at most of studied ages (P0 $p < 0.05$, P7 $p < 0.001$, P14 $p < 0.01$, P22 $p < 0.001$), but no confirmation of potential *Brn3a*-mediated regulation (Fig. 9*e*, Additional file 1: Table S1). Selective expression of *Pnkd* transcripts will be described below (Fig. 14). *Rims1* (regulating synaptic membrane exocytosis 1) transcript and gene expression is



enriched in RGCs vs. retina, but only transcript-specific RNASeq analysis reveals Brn3a-dependent differential expression (Fig. 9f-f^{II}). ISH confirms strong and significant GCL enrichment throughout postnatal development (WT retinas $p < 0.001$, Additional file 1: Table S1) and reveals some high-expressing cells in both the INL and GCL (Figs. 8f, 9f). Expression of Rims1 is high from P0-P14, and slightly decreases in the adult. Its dependency on Brn3a was apparent at P14 ($p < 0.05$) and becomes more significant in the adult ($p < 0.001$) (Fig. 9f, Additional file 1: Table S1 D-E).

Secreted proteins (Figures 10 and 11)

RNASeq results predicted Brn3a^{AP/WT} RGCs enrichment and Brn3a regulation for Fam19a4 (family with sequence similarity 19, member A4) (Fig. 11d^{I-d^{II}}), however ISH showed only low level of GCL staining exclusively at P3-P7 without visible regulation by Brn3a (Fig. 10a). The only detectable Nptx1 (neuronal pentraxin 1) RefSeq transcript (Fig. 11a^{II}) is expressed in all retina samples however it is significantly enriched in Brn3a^{AP/WT} RGCs and regulated by Brn3a, which is in agreement with RNASeq gene level analysis (Fig. 11a^I). ISH largely confirms these findings, showing intense GCL staining beginning with P0 and persisting into the adult (Figs. 10b, 11a). Starting at P14 intense signal also appears in the INL, in a position consistent with Amacrine cell expression (Fig. 10b), but the significant GCL enrichment persists (P14 and P22 WT retinas $p < 0.001$, Fig. 11a). The GCL signal appears to be Brn3a dependent at the later ages (P14 and P22, $p < 0.05$), as it is significantly reduced in Brn3a KO retinas (Figs. 10b and 11a, Additional file 1: Table S1 D-E). Nptx2 (neuronal pentraxin 2) is GCL enriched and Brn3a-regulated according to transcript and gene level RNASeq (Fig. 11b^{I-b^{II}}). In ISH (Fig. 10c) Nptx2 labels fewer cell bodies in the GCL compared to Nptx1, however it is also GCL enriched in the Brn3a WT at P3 ($p < 0.001$), P7 ($p < 0.01$) and adult ($p < 0.01$) but not regulated significantly by Brn3a (Figs. 10c and 11b, Additional file 1: Table S1). Sez6l2 (seizure related 6 homolog-like 2) has 3 transcripts with very diverse profiles of expression at P3 (NM_001252567, NM_144926 and NM_001252566, Fig. 11c^{II-c^{IV}}). NM_001252567 is highly expressed in both RGCs and retina, except Brn3b KO retina, and it is the only Brn3a-dependent isoform (Fig. 11c^{II}). NM_144926 is strongly represented in Brn3a RGCs and, surprisingly, in Brn3b KO retina, and is not regulated by Brn3a (Fig. 11c^{III}). NM_001252566 expression is evenly distributed between RGCs and retina, with some enrichment in Brn3a RGCs (Fig. 11c^{IV}). Gene level analysis does reveal Brn3a RGC enrichment, but it does not demonstrate any Brn3a dependency (Fig. 11c^I). ISH using a 3'-UTR probe common for all three isoforms shows GCL enrichment

throughout the larger part of postnatal development (P0-P14, Figs. 10d, 11c, Additional file 1: Table S1) and significant signs of Brn3a regulation in the GCL at P0 and P7 ($p < 0.05$). However, in the adult the GCL signal in Brn3a WT and KO retinas is indistinguishable (Figs. 10d, 11c).

Adhesion molecules and other transmembrane proteins (Figures 12 and 13)

Both transcript and gene level RNASeq analyses demonstrated that Cdh4 (cadherin 4) is significantly enriched in Brn3a^{AP/WT} RGCs in comparison to all other retinal and RGC samples, including Brn3a^{AP/KO} RGCs, suggesting regulation by Brn3a in specific RGC populations (Fig. 13a^{I-a^{II}}). ISH reveals that Cdh4 is already expressed and GCL enriched at P0 (Figs. 12a, 13a), the expression increases at P3, and it is sparse in both GCL as well as INL. The distribution of INL staining is consistent with horizontal cell and amacrine cell expression (Fig. 12a). The number of Cdh4⁺ cells in the Brn3a KO GCL is consistently smaller compared to Brn3a WT throughout postnatal development, and the quantitation confirms it for the majority of studied ages (P0 $p < 0.001$, P3 $p < 0.05$, P14 $p < 0.01$, P22 $p < 0.05$, Additional file 1: Table S1). According to our RNASeq results Pcdh20 (protocadherin 20) is enriched in Brn3a^{AP/WT} RGCs relative to other RGC and retina samples, although its general level of expression is comparatively low (Fig. 13b^{I-b^{II}}). It is decreased in both Brn3a^{AP/KO} and Brn3b^{AP/KO} RGCs, suggesting regulation by both transcription factors, although, due to its low expression level (< 2 FPKM for the transcript) in Brn3b^{AP/WT} RGCs Pcdh20 was not selected as a Brn3b regulated gene in the screen. ISH showed very low levels of expression from P0 to P7, and a modest GCL enrichment (KO $p < 0.001$, WT not significant) and differential regulation by Brn3a ($p < 0.05$) at P14 (Figs. 12b, 13b, Additional file 1: Table S1 D). Both gene and transcript RNASeq analyses show that Rtn4rl2 (reticulon 4 receptor-like 2) is rather homogeneously distributed between RGCs and the retina (Fig. 13c^{I-c^{II}}). Transcript analysis also reveals a high differential between Brn3a WT and KO RGCs (Fig. 13c^{II}). ISH shows that Rtn4rl2 is GCL enriched early (P0-P3), and then the distribution changes after P7 and the level in the INL becomes significantly higher than in the GCL (P7 WT $p < 0.001$, KO $p < 0.01$, Figs. 12c, 13c, Additional file 1: Table S1 C). Tmem25 (transmembrane protein 25) has only one RefSeq transcript expressed in the retina. Despite both transcript and gene level RNASeq analyses show enrichment in Brn3a WT RGCs, the gene level diagram does not show regulation by Brn3a in RGCs probably due to the contribution of non-RefSeq transcripts (Fig. 13d^{I-d^{II}}). In situ developmental profile shows GCL enrichment of the expression at P0 (WT $p < 0.05$), P14 (WT $p < 0.001$) and

P22 (WT $p < 0.001$), but no considerable signs of Brn3a-mediated regulation (Figs. 12d, 13d, Additional file 1: Table S1). Tmem91 (transmembrane protein 91) has two transcript isoforms (NM_001290497 and NM_177102, Fig. 13e^{II-e^{III}}), both of them show a modest expression in retina and RGCs. NM_001290497 is differentially expressed in Brn3a^{AP/WT} RGCs compared to Brn3a^{AP/KO} RGCs, NM_177102 is not, and probably because of this gene level analysis does not reveal differential regulation by Brn3a (Fig. 13e^I). ISH confirms expression of Tmem91 starting at P0-P3, increasing through P7-P14, and diminishing in P22 (Fig. 12e). It also shows a significant differential between Brn3a WT and Brn3a KO GCL expression at P7 ($p < 0.001$) and P14 ($p < 0.01$) (Figs. 12e, 13e, Additional file 1: Table S1 C-D).

Combined RNASeq, RT-PCR and ISH analysis for specific transcript isoform expression

Many of the described candidate genes (Figs. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13), selected based on the presence of at least one transcript enriched in Brn3a^{AP} RGCs and regulated by Brn3a, had several transcript isoforms expressed in the retina, often showing distinct expression patterns. The ISH tests performed with 3'-UTR probes common to all transcripts (Table 1) did therefore report a combination of the expression patterns and levels of these different transcripts, thus reflecting essentially a "gene level" expression profile. Whereas it is important to understand the expression pattern of our candidates at gene level, some biologically relevant functions could be dependent on the expression of specific isoforms. We therefore decided to further investigate the differential expression for transcripts of two genes predicted to have multiple retina-specific isoforms, Pnkd and Clcc1.

Pnkd transcripts detected in the retina

According to RNASeq data, 3 Pnkd transcripts are expressed broadly among retina and Brn3^{AP} RGC samples (Fig. 14a-b). The long isoform (NM_001039509), initiated at exon 2, and skipping exons 4 and 5 (green splicing sequence, Fig. 14b) is enriched in both Brn3a^{AP/WT} and Brn3b^{AP/WT} RGCs, but only regulated by Brn3b. The "medium" transcript (NM_019999), predicted to start at exon 5 (purple splicing sequence, Fig. 14b), is enriched in RGCs but regulated by Brn3a. The "short" transcript isoform (NM_025580), spans three exons (e2, e3 and e4, blue splicing sequence, Fig. 14b), and shows no enrichment in RGCs. A further putative transcript, initiating at exon 1, was not detected by RNASeq in the retina or RGCs (gray splicing sequence, Fig. 14b). We sought to confirm the existence of these alternative transcripts by using RT-PCR analysis from P3 retina RNA

(Fig. 14b, c; Tables 1 and 2). Bands for all positive reactions were cloned and confirmed by sequencing.


The reaction of primers 1 and 2, common to the short (NM_025580) and long (NM_001039509) transcripts, resulted in the expected product length, equal to combined exons 2 and 3. However, primers 3 + 4, recognizing exon 4, specific for the short isoform, did not produce any RT-PCR fragment, suggesting that this transcript (NM_025580) is not present in P3 retina. Primer combinations 5 + 6, and 5 + 7, specific for the exon 5 or the sum of exons 5 and 6 respectively, are selective for the medium isoform (NM_019999). Both reactions resulted in the correct product sizes (Tables 1 and 2, Fig. 14b, c). In summary, the RT-PCR analysis suggests that the long (NM_001039509) and medium (NM_019999) transcripts are expressed at detectable levels in the retina, while the short (NM_025580) transcript is not. Finally, to look at the temporal and spatial distribution of Pnkd isoforms in the retina, we generated isoform specific probes covering the long (Pr1 + Pr2), medium (Pr5 + Pr6) and short (Pr3 + Pr4) transcripts and screened our panel of postnatal retina sections (Fig. 14b, d). The long isoform is expressed at low levels in a GCL-specific manner beginning with P3 and continuing into adult (Fig. 14d, left). The medium transcript is highly expressed in the GCL from P0 to P22, but INL expression picks up at P3 and persists into the adult (Fig. 14d, middle). There is little or no Brn3a regulation for either the long or medium isoform. The short isoform was not observed in either Brn3a WT or KO retinas from P0 to P22, right column. It should be noted that the signal intensity for the medium isoform is much stronger than the one seen for the 3'-UTR probe (Fig. 8e), that should be common for both long and medium (but not short) isoforms, but the differential between signal intensity in GCL and other retinal layers is conserved between these two probes. Taken together these results suggest that Pnkd is expressed in the retina, predominantly in the GCL, but also in the INL. Whereas the enrichment of long and medium isoforms in the GCL, predicted by RNASeq data, is confirmed, the relative level of expression of the transcripts, as judged by ISH, is not entirely consistent with the RNASeq predictions. Moreover, the ubiquitous retinal expression of the short isoform, predicted by RNASeq, is not confirmed by either RT-PCR or ISH.

Clcc1 transcripts detected in the retina

GeneBank annotation predicts that Clcc1 has five transcript isoforms, consisting mostly of alternative, partially overlapping sequences for exon 1, resulting from 4 alternative transcription start sites and three different exon1 3' ends: NM_145543 – exon 1a, XM_006501416 – exon 1b, NM_001177771 – exon 1c, XM_011240107 – exon 1d, NM_001177770 – exon 1e. Exon 2 is included only in transcript NM_001177771 (Fig. 15b). Our RNASeq

data predicted three retinally expressed *Clcc1* transcripts: NM_145543, NM_001177771 and NM_001177770 (Fig. 15a, b). NM_145543 (Fig. 15b, green splicing sequence) is highly expressed in RGCs and retina, with lowest expression levels in *Brn3a*^{AP/WT} and *Brn3a*^{AP/KO} RGCs (Fig. 15a, left). In contrast, NM_001177771 (Fig. 15b, blue splicing sequence) is considerably expressed only in *Brn3a*^{AP/WT} RGCs (Fig. 15a, middle), predicting both specificity for *Brn3a* RGCs and regulation by *Brn3a*. Finally, NM_001177770 (Fig. 15b, gray

splicing sequence) is expressed moderately in both retina and RGCs (Fig. 15a, right). Given the large degree of overlap between *Clcc1* isoforms, and the presence of potential alternative open reading frames, we were interested to map out the precise boundaries of exon 1 variants. We performed RT-PCR from P3 retina samples using primers targeted to specific exon regions of each transcript (Tables 1 and 2, Fig. 15b-d). All positive bands were subcloned and confirmed by sequencing. Primers 10 and 11 were used to diagnose a product



spanning exons 4, 5 and 6, common to all transcript variants (~ 400 bp, Fig. 15b-d).

Forward primers Pr1 to Pr6, tilling all possible exon 1 variants, were individually paired with reverse primer Pr9, placed in exon 3, the first common exon for all splicing isoforms. Combinations of Pr1 to Pr5 with Pr9 resulted in product lengths consistent with the presence of exon variants 1a, and 1b, and excluding variants 1c, 1d and 1e (Fig. 15b-d, and see Table 2 for product lengths). E.g., the primer combination Pr2 + Pr9 gave 2 bands corresponding to XM_006501416 (exon e1b, longer fragment, ~ 300 bp) and NM_145543 (exon 1a, shorter fragment, ~ 200 bp), while combination Pr1 + Pr9 gave only one band ~ 200 bp for NM_145543 as expected. The combination of Pr6 + Pr9 showed only nonspecific bands (small amount and incorrect size), thus excluding isoforms XM_011240107 and NM_001177770 (exons 1d or 1e spliced to exon 3). All primer combinations detecting splicing sequences including exons 1 and 2 (forward Pr2, Pr3, Pr4, Pr6 combined with reverse Pr8) failed to give a positive reaction. However, splicing of exon 2 onto exon 3 is occurring, since the combination of forward primer Pr7 (5' end of exon 2) and reverse Pr9 gave a positive reaction of expected length and sequence. Pr7 + Pr8 produced the expected size product (see below). In summary, our RT-PCR analysis narrows the number of *Clcc1* transcripts expressed in the retina to NM_145543 and XM_006501416, and proposes a new alternative transcript initiating at exon 2. This novel transcript would explain the reads assigned to NM_00117771, that follows the splicing sequence e1 - e2 - e3, which we could not detect in the retina. We next determined the cellular distribution and developmental profile of the retinally expressed *Clcc1* isoforms by ISH. The combined expression pattern of NM_145543 and XM_006501416 was determined using a probe that spans the exon 1b to exon 3 splicing event (Pr2 + Pr9, long product), while the novel transcript variant was tested using a probe against its unique exon 2 (Pr7 + Pr8). We find that the exon 2-containing transcript is expressed in the GCL starting with P3 and the INL beginning with P7. The GCL signal persists into the adult age and shows only a modest differential in Brn3a KO vs. WT retinas (Fig. 15e, right column), while ISH signal generated by the combined expression level of NM_145543 and XM_006501416 was relatively low throughout postnatal development (Fig. 15e, left column). In summary, only three *Clcc1* transcript isoforms are present in retina: NM_145543, XM_006501416, and a novel uncharacterized transcript containing exons 2 and 3. The three isoforms are predicted to encode the same protein, with the translation initiation site located in exon 3, however, they have three distinct transcription start sites.

Immunohistochemical analysis of two potential Brn3a targets – *Elfn1* and *Cdh4*

We have focused so far on validating expression of potential Brn3a target molecules at the mRNA level. However, we are ultimately interested in the potential roles played by the encoded proteins in RGC cell type formation. We therefore sought to determine the cell type distribution and cellular localization of some of our targets. We show here results for two adhesion molecules playing potential roles in dendrite lamination and synaptic development, *Cdh4* and *Elfn1*, during one developmental time point (P7) and in the adult (P22).

At P7, *Elfn1* expression is found in RGCs, Amacrine, Horizontal cells and Photoreceptors (Fig. 16a-b). Some *Elfn1*⁺ RGCs (identified by co-labelling with AP generated from the recombined *Brn3a*^{AP} allele) show intense staining in proximal dendrites. By P22, intense and punctate *Elfn1*⁺ staining is visible in the OPL (Fig. 16c-d). A distinct *Elfn1*⁺ lamina is visible in the IPL of Brn3a WT retinas, but essentially absent in Brn3a KO retinas. This suggests that at least one *Elfn1*⁺ cell type, presumably an RGC, is either deleted or has an altered morphology in Brn3a KO retinas. Alternatively, *Elfn1* could be under Brn3a transcriptional control (Fig. 16c, d, i, j).

Cdh4 is expressed at P7 in RGCs, Amacrine and Horizontal cells. Strongly labeled *Cdh4*⁺ cell bodies in the INL most likely belong to Amacrine and Horizontal cells and are observed at both P7 and P22 (Fig. 16e-h). RGC staining does not seem to persist in the adult Brn3a WT retina (Fig. 16g). One *Cdh4*⁺ lamina is present in the IPL at P7 (Fig. 16e-f), while two laminae appear intensely *Cdh4*⁺ in the adult (Fig. 16g-h). None of these laminae is significantly affected by Brn3a ablation at either P7 or P22 (Fig. 16g, h, k, l). Unlike for *Elfn1*, a strong OPL *Cdh4*⁺ positive staining emerges already at P7. In conclusion, whereas both *Elfn1* and *Cdh4* were somewhat enriched in RGC during early postnatal development, adult patterns of expression include multiple other cell types, and RGC expression of *Elfn1* appears profoundly regulated by Brn3a in the adult stage, while *Cdh4* RGC expression levels decline to undetectable levels in both WT and Brn3aKO GCL.

Discussion

We report here the results of a screen for genes potentially involved in mediating the effects of transcription factor Brn3a in RGC type specification. The screen covered 5 postnatal ages, between P0 and adult, and employed ISH, RT-PCR, and immunohistochemistry. The genes were selected using data from a previously published RNASeq screen for Brn3a candidate target genes in P3 RGCs [5], and had to have at least one transcript satisfying the following three criteria: 1) expression of at least 2 FPKM in Brn3a^{AP} RGCs; 2) expression




Fig. 16 (See legend on next page.)

(See figure on previous page.)

Fig. 16 Distinct *Brn3a* effects on the expression of two adhesion molecules – *Elfn1* and *Cdh4*. Retinal sections were prepared from either *Rax:Cre; Brn3a^{CKOAP/WT}* (a, c, e, g) or *Rax:Cre; Brn3a^{CKOAP/KO}* (b, d, f, h) mice at P7 (a, b, e, f) or P22 (c, d, g, h). Immunostaining for either *Elfn1* (green, a-d) or *Cdh4* (green, e-h) was performed in conjunction with immunostaining for *Brn3a^{AP}* RGCs (red, AP) and nuclear layers counterstain (DAPI, in blue, in merge channel). For every immunostaining *Elfn1* (left), AP (middle) and merge (right) channels are shown. White arrowheads, asterisks and arrows indicate Horizontal Cells, Amacrine Cells and RGCs. Green arrowheads in C and D reveal synaptic staining in the OPL, as previously reported [81]. Green stippled lines in the merge channel indicate lamination of *Elfn1⁺* or *Cdh4⁺* neurites in the IPL, if present. Scale bar in H = 50 μ m. **i-l** Schematics of *Brn3a^{AP}* RGCs dendrites (red) and *Elfn1* (orange, I, J) and *Cdh4* (green or orange, K, L) lamination in the IPL, at P7 (I, K) or P22 (J, L), in *Rax:Cre; Brn3a^{CKOAP/WT}* (left, WT) or *Rax:Cre; Brn3a^{CKOAP/KO}* (right, KO) retinas. *Elfn1* stains only a few diffuse dendrites at P7, however a sharp lamina is labelled in P22, and this lamina is absent from *Brn3a* null retinas. *Cdh4⁺* dendrites form one clear lamina at P7 and two distinct laminae at P22, however the lamination pattern is not affected by *Brn3a* ablation

enrichment of two-fold in *Brn3a^{AP/WT}* RGCs compared to the retina; 3) downregulation of at least two-fold between *Brn3a^{AP/WT}* and *Brn3a^{AP/KO}* RGCs. From the 180 transcripts satisfying these criteria in the original screen, we narrowed our search to genes whose molecular structure suggested potential functions in cell type specification, i.e. transcription, translation, intracellular signaling, synapse formation and function, vesicular transport or release, secreted and cell surface molecules. Of the 28 selected genes, a majority (20/28) showed increased GCL signal compared to the retina, but only a small fraction (4/28) exhibited significant *Brn3a* regulation at P3 (Table 3). Moreover, the expression profile of most candidate genes was extremely dynamic during postnatal development, and only a handful exhibited RGC enrichment and/or *Brn3a* regulation throughout all developmental ages.

Differential expression: RNASeq, ISH and developmental dynamics

What molecules with potential to influence RGC type specificity are *Brn3a* targets? The gene expression profiling screen at the origin of this study was focused on postnatal day 3 and looked at *Brn3a* RGC specific transcripts. Our reasoning was that P3 is a particularly active time point for neurite branching and synapse formation for both RGC dendrites and axons. However, RGCs, which become postmitotic beginning with E12.5, are probably amongst the most mature neurons in the early postnatal retina. Thus, by selecting genes that had transcripts with higher expression levels in *Brn3a* RGCs versus retina supernatants, it is likely that we included molecules enriched in mature neurons. In addition, transcript and gene level RNAseq analysis reveals that many of our target genes had RGC specific as well as more broadly expressed transcripts. Thus, using probes placed in the 3'UTR, typically recognizing most transcripts of a gene, will necessarily miss some of the differences predicted by RNASeq at the transcript level. Nevertheless, it is important to know the overall gene expression levels for any given gene in the retina and RGCs, in order to better predict and understand phenotypic changes upon loss of function manipulations. Taken all

these considerations into account, it is rewarding to find that gene-level ISH confirmed RGC enrichment for about two thirds of the targets (20 of 28, 71% accuracy), and slightly more than half for *Brn3a* dependent RGC expression at any given age (16 of 28, 57% accuracy). A subset of our targets, (*Rbfox1*, *Eml1*, *Hpca*, *Mapk10*, *Pick1*, *Pnkd*, *Sez6l2*, *Tmem91*) had multiple RefSeq transcripts, some of which were not *Brn3a* dependent; with gene level RNASeq analysis did not show *Brn3a* dependency. This could explain why, for all these genes, ISH using the 3'UTR did not show differences of expression at P3. It is however worth mentioning that *Mapk10* appeared *Brn3a* dependent at all other studied ages. Another 16 targets (*Foxp2*, *Plppr3*, *Pip5kl1*, *Pak6*, *Ankrd13b*, *Elfn1*, *Gabra1*, *Grm4*, *Ntrk1*, *Rims1*, *Fam19a4*, *Nptx1*, *Nptx2*, *Pcdh20*, *Rtn4rl2*, *Tmem25*) have only one expressed transcript each, predicted to be *Brn3a*-dependent. Exactly half of those genes (8 of 16) seem to be significantly regulated at postnatal ages other than P3 (*Foxp2* – P7, P22; *Plppr3* – P14; *Elfn1* – P14-P22; *Gabra1* – P22; *Rims1* – P14-P22; *Nptx1* – P14-P22; *Pcdh20* – P14; *Rtn4rl2* – P7), but another half (*Pip5kl1*, *Pak6*, *Ankrd13b*, *Grm4*, *Ntrk1*, *Fam19a4*, *Nptx2*, *Tmem25*) do not reveal any signs of *Brn3a*-mediated regulation at any stage of postnatal development. Of note, the presence of *Brn3a* independent transcripts was a strong predictor of lack of *Brn3a* regulation at gene level. However the presence of only one, *Brn3a* dependent RefSeq transcript was not necessarily linked with gene level regulation, or confirmation by ISH, most likely suggesting the existence of further, non-RefSeq transcripts (e.g. *Pip5kl1*, *Ankrd13b* and *Tmem25*).

Among the molecules that were confirmed by ISH to be *Brn3a*-dependent at P3 we found mRNAs for transcription factor *Tshz2*, vesicle-associated proteins *Snap91* and *Tusc5*, and adhesion protein *Cdh4*. While *Tshz2* and *Snap91* mRNAs show only transient *Brn3a* dependency, *Tusc5* and *Cdh4* represent developmentally consistent *Brn3a* regulation targets (Table 3). *Mapk10* showed fairly consistent *Brn3a*-dependency (with the exception of P3, Figs. 4d, 5d). *Brn3a* regulation could be hidden by *Brn3a*-negative RGC types, or by non-RGC

Table 3 The expression of Brn3a target genes: ISH and RNASeq results comparison

| Gene | Known function | GCL P3 | GCL P0- P22 | Brn3a target P3 | Brn3a target any age | Postnatal GCL Expression | | | GCL Sparse | Brn3a- independ. Transcripts | Brn3a- regulation Gene level |
|---|---------------------------------------|-----------|-------------------|-----------------------|-------------------------------|--------------------------|---------|--------|---------------|------------------------------------|------------------------------------|
| | | | | | | Onset | Peak | Offset | | | |
| Transcriptional and translational regulators | | | | | | | | | | | |
| Foxp2 | TF | yes | no | no | yes | P0 | P7 | no | no | no | yes |
| Tshz2 | TF | yes | yes | yes | yes | P3 | P7 | no | no | no | yes |
| Rbfox1 | Splicing of neuronal genes | yes | no | no | no | P0 | P14 | no | no | yes | no |
| Intracellular signaling and cytoskeleton-associated genes | | | | | | | | | | | |
| Eml1 | Microtubule-binding protein | yes | no | no | no | P0 | P7 | no | no | yes | no |
| Hpca | Calcium sensor | yes | yes | no | yes | P0 | P7-P14 | no | no | yes | no |
| Plppr3 | Neurite growth and regeneration | yes | yes | no | yes | P0 | P0 | no | no | no | no |
| Mapk10 | Axonal growth and neuronal survival | yes | yes | no | yes | P0 | P7-P14 | no | yes | yes | no |
| Pip5k1 | Cell morphology and adhesion | no | no | no | no | P3 | P7 | no | no | no | no |
| Pak6 | Signaling kinase | no | no | no | no | no | no | no | no | no | na |
| Vesicle-associated proteins | | | | | | | | | | | |
| Ankrd13b | Caveolin- mediated endosomal traffick | yes | yes | no | no | P0 | P7 | no | no | no | no |
| Pick1 | Glutamate receptor trafficking | yes | no | no | no | P0 | no | no | no | yes | no |
| Snap91 | Clathrin-mediated endocytosis | yes | yes | yes | yes | P0 | P7-P14 | no | yes | yes | no |
| Tusc5 | Insulin-stimulated glucose transport | yes | yes | yes | yes | P3 | P14 | no | yes | no | yes |
| Synapse-associated proteins | | | | | | | | | | | |
| Elfn1 | Synaptic adhesion protein | yes | no | no | yes | P3 | P7 | no | yes | no | yes |
| Gabra1 | GABA receptor alpha1 subunit | no | no | no | yes | P3 | no | no | yes | no | yes |
| Grm4 | Metabotropic glutamate receptor | yes | no | no | no | P0 | P7 | no | no | no | yes |
| Ntrk1 | Neurotrophin receptor | yes | no | no | no | P0 | P14-P22 | no | no | no | yes |
| Pnkd | Synaptic vesicle release | no | yes | no | no | P0 | P7-P14 | no | yes | yes | no |
| Rims1 | Synaptic vesicle release & recycling | yes | yes | no | yes | P0 | P0-P3 | no | yes | no | no |
| Secreted proteins | | | | | | | | | | | |
| Fam19a4 | Unknown | no | no | no | no | P3 | P3-P7 | P7 | no | no | yes |
| Nptx1 | Trans-synaptic, excitatory synapse | yes | yes | no | yes | P0 | P14 | no | yes | no | yes |
| Nptx2 | Trans-synaptic, excitatory synapse | yes | no | no | no | P3 | P7-P14 | no | yes | no | yes |
| Sez6l2 | Synapse formation | yes | yes | no | yes | P3 | P7 | no | no | yes | no |
| Adhesion molecules and other transmembrane proteins | | | | | | | | | | | |
| Cdh4 | Cell adhesion molecule | yes | no | yes | yes | P0 | no | no | yes | no | yes |
| Pcdh20 | Cell adhesion molecule | no | no | no | yes | P14 | no | no | no | no | yes |
| Rtn4rl2 | Axon guidance molecule | yes | yes | no | yes | P0 | no | P22 | no | no | no |
| Tmem25 | Unknown | no | no | no | no | P0 | P7-P14 | no | no | no | no |
| Tmem91 | Unknown | no | no | no | yes | P0 | P7-P14 | no | no | yes | no |

Column 1 represents gene name, column 2 – known function of the gene, column 3 – GCL enrichment at P3, column 4 – consistent GCL enrichment (at least at 4 out of 5 ages) from P0-P22. Fifth column shows whether the gene is regulated by Brn3a at P3, 6th – regulated by Brn3a at any of 5 studied ages. Columns 7, 8 and 9 represent the onset, the peak and the offset respectively of postnatal gene expression in the GCL. Column 10 shows whether the gene is highly and sparsely expressed in the GCL at any of studied ages. Columns 11 and 12 identify the genes that had unregulated transcripts or exhibited gene level regulation by RNASeq

expression in the ganglion cell layer which derives from Amacrine cells. In case of genes regulated by Brn3a early (P3-P7), but not late (P14-P22) (for instance, Snap91), delayed expression could occur in Brn3a-independent RGC subtypes or in Amacrine cells. A subset of targets

(Elfn1, Gabra1, Rims1, Nptx1 and Pcdh20) which are GCL-expressed and Brn3a-regulated at later ages (P14-P22), are potentially more important during RGC synapse maturation in the retina after eye-opening and for Brn3a-expressing RGC function. Our findings

suggest that patterns revealed by RNA sequencing may only partially be reproduced by other detection techniques. In addition, many genes may change their pattern of expression over time, especially when samples are derived from rapidly developing tissues, such as early postnatal retina. These dynamic expression profiles could also suggest the developmental steps at which the various target genes might be involved, as described below.

Transcript level analysis of cell type specificity

Many of the candidate genes identified in our RNAseq screen had two or more transcripts, with mixed patterns of RGC enrichment and/or Brn3a regulation. We therefore tested the accuracy of transcript level analysis and its influence on diagnosing cell type specificity of gene expression for two candidate genes – Pnkd and Clcc1, using transcript-specific RT-PCR reactions and ISH probes. We chose Pnkd since it has three previously characterized transcripts, encoding different protein isoforms, with the long version, Pnkd-L (long transcript) thought to be CNS-specific [52]. For Pnkd (3 predicted retinal transcripts - long, medium and short), only one transcript was predicted by RNASeq to be Brn3a-dependent. Both RT-PCR and ISH confirmed the RGC enrichment of the Pnkd medium transcript suggested by RNAseq for P3 retina. However, there was a strong discrepancy between the relative abundance of the long and medium size transcripts as reported by RNASeq and ISH, and the third, short isoform was undetectable by either RT-PCR or ISH. Furthermore, the ISH signal intensity was far stronger for the medium transcript specific probe compared to the 3'UTR probe detecting all isoforms, although hybridization strength based on base pair composition and probe length (360 bases for 3'-UTR and 167 bases for medium transcript) favor the 3'UTR probe. Clcc1 has an unusually large number of exon 1 variants – based on different transcription start sites and exon 1 splice donor sites. Also, Clcc1 transcript NM_001177771 was predicted to be highly expressed specifically in Brn3a WT and not in Brn3a KO RGCs or other parts of retina. Clcc1 has 5 alternative transcripts, mostly based on alternative transcription start sites at exon 1. Of the three predicted retina specific variants, one (NM_001177771) was supposed to be highly differentially expressed in Brn3a^{AP/WT} RGCs and regulated by Brn3a. Our RT-PCR analysis with transcript-specific primers did not confirm the expression of this isoform, but rather suggests the presence of a novel, closely related transcript initiated at exon 2, and splicing onto exon 3. This novel isoform was found to be GCL-enriched by ISH at P3 but expanded its expression to the INL from P7 to P22. The encoded protein should be the same for NM_001177771 and the

novel isoform since the open reading frame starts at exon 3, shared by both. Moreover, long exon 1 variants (NM_001177770 and XM_011240107) were not confirmed in our experiments, suggesting that there is no basis for existence of alternative protein variants with an open reading frame start at exon 1. Taken together, the outcomes of the transcript level analyses for Pnkd and Clcc1 raise several points to be considered when evaluating RNASeq predictions of cell type specificity. Transcript level analysis by RNASeq is constrained to aligning reads onto the existing transcript annotations, and hence relies on their quality. In addition, it could misrepresent the relative abundance of existing transcripts if it relies on reduced read numbers that do not span exon boundaries. In the case of Clcc1, the challenge was particularly steep given the large number of annotated alternative transcription start sites and splice donor sites at exon 1. Since most RNASeq data are derived from mRNA by using poly-dT capture of the polyA at the 3' end, this last issue could be particularly severe at the 5' end of the mRNA, as seen for both Pnkd and Clcc1. RNASeq results could be biased by amplification artefacts, while ISH detection could be influenced by the specific sequence properties of the used probes, as seen for the Pnkd medium isoform. Although, for both tested genes, a careful transcript level analysis did explain the RNASeq predictions, our data argues for using the deep sequencing predictions as a starting point for more careful transcript characterization.

Transcription and translation – related targets

The two identified transcription factors, Foxp2 and Tshz2 [53, 54] are expressed and GCL-enriched early in postnatal development (P0-P7), however at P14 – P22 Tshz2 expression is reduced but limited to the GCL, while Foxp2 expression extends to include both INL and GCL. This is somewhat surprising since recent reports suggest that retinal Foxp2 expression is restricted to a subset of RGC types [55, 56]. However, a transiently broader pattern of expression is suggested by using a Foxp2^{Cre} crossed into a general reporter [55]. Although Foxp2 missense mutations are associated with speech impairment in humans, the gene has clearly a broader developmental role, as mouse loss of function alleles result in lethality at 3–4 weeks of age [57]. Tshz2 is one of the three homologues of the *Drosophila* transcription factor teashirt, a gene involved in the homeotic control of body segment and imaginal disc formation that cooperates with eyeless (Pax6) in establishing fly retina identity [54]. Tshz2 has not been studied in great detail, however, mouse ISH data reveals cell type specific localization in several brain regions [58], suggesting a role in cell type specification. Thus, both identified TFs are good candidates for mediating Brn3a roles in RGC

type specification. The splicing regulator *Rbfox1* is enriched but not restricted to the GCL beginning with P3, and eventually expands to the whole retina by adult age. This could reflect a role in neuronal maturation, by regulating splicing of mRNAs for proteins implicated in synapse transmission and plasma membrane potential formation [59], especially during the period of active synaptogenesis (P3-P14) when its level is high according to our data.

Intracellular signaling components

We characterized the expression of five genes involved in intracellular signaling cascades. *Eml1* is a microtubule-binding protein, and its disruption results in the generation of ectopic neuronal progenitors in the cerebral cortex of both mouse and human [60]. Interestingly, the fish homologue of *Eml1* is expressed in photoreceptors and mediates Ca^{2+} modulation of the cyclic GMP gated channel [61, 62]. *Hpca* is a calcium sensor protein modulating slow afterhyperpolarization in the brain [63], but with many other suggested functions in morphogenesis. *Mapk10* encodes the signaling molecule *Jnk3* implicated in axonal growth and regeneration and neuronal survival [39, 64]. *Plppr3* is a member of the lipid phosphate phosphatase-related protein family, which share sequence homology with known phosphatases but are catalytically inactive due to substitutions in known key aminoacids in the catalytic domains. They are five pass transmembrane proteins, were shown to stimulate membrane protrusions and neurite growth in cell lines and primary neuron culture and facilitate axonal outgrowth and regenerative sprouting [65, 66]. *Pip5kl1* is a brain-specific, kinase-dead isoform of phosphatidil-inositol-(4)-phosphate 5-kinase, operating as a scaffold for recruitment of other phosphatidil inositol 5 – kinases, and implicated in cell morphology control and adhesion foci [67]. *Eml1*, *Hpca*, and *Mapk10* were all expressed in the GCL beginning with P0 with a peak around P7-P14, and persistence into the adult. Their early and persistent pattern of expression is consistent with participation in both molecular and activity dependent processes, beyond the period of eye-opening (~P14) [68, 69]. The two molecules involved in phospholipid signaling, *Plppr3* and *Pip5kl1*, follow different trends. *Plppr3* expression is strong already at P0, and decreases dramatically towards adult, while *Pip5kl1* is expressed in the GCL, although transiently (P3-P7) and at low levels. This expression profile suggest roles in the early stages of dendrite formation and/or axon branching.

Three of the genes encoding vesicle-associated proteins – *Ankrd13b*, *Pick1* and *Snap91* – also showed early expression in the GCL (P0 – P3), with gradual expansion of the signal in both the GCL and the INL from P3 till

adult age. *Ankrd13b* participates in caveolin-1 mediated endosomal trafficking [70]. *Pick1* is involved in glutamate receptor trafficking [71], while *Snap91* is implicated in clathrin-mediated endocytosis, and participates in axogenesis and dendritic growth in hippocampal neurons [72]. *Tusc5* is the only gene from this group showing strong and sparse GCL signal that is *Brn3a* dependent, beginning with P3. It was shown before to regulate insulin-stimulated glucose transport in adipocytes [73], but it is also expressed in peripheral neurons [74] and olfactory receptors [75].

Synapse associated molecules

The expression dynamic observed for intracellular signaling and vesicle associated proteins is largely followed by most synapse-associated genes explored in our screen, i.e. *Gabra1*, *Grm4*, *Ntrk1* and *Pnkd*. Early (P0 or P3) GCL enrichment is followed by expansion of the expression domain into the INL towards the adult ages. Later the expression patterns diversify. *Gabra1* becomes highly but sparsely expressed in the INL and GCL, and exhibits *Brn3a* regulation in the GCL, while *Grm4* and *Ntrk1* expression is broad in the INL and the GCL. The expression for both *Grm4* (encoding the metabotropic glutamate receptor mGluR4 [76]) and *Gabra1* (encoding the GABA (gamma amino butyric acid) receptor alpha 1 subunit) [77, 78] have been previously characterized in the retina at the protein level. Both receptors exhibit characteristic lamination profiles in the IPL. Our in situ data now shows that mGluR4 (*Grm4*) and *Gabra1* are expressed in Bipolar, Amacrine and Ganglion cells, and thus could participate in Bipolar-Amacrine-RGC triad synapses at both pre-and postsynaptic sites, as suggested for the cerebellum [79]. The recently characterized synaptic molecule *Elfn1* is also expressed pre- and post-synaptically in multiple neuronal cell types [80–82]. It presumably acts as a trans-synaptic adhesion molecule, and regulates pre-synaptic release probability of certain hippocampal neurons [82]. In the retina, *Elfn1* was shown to participate in establishment of Photoreceptor-Bipolar Cell contacts via trans-synaptic interaction with metabotropic glutamate receptor mGluR6 [81]. Our ISH reveals high levels of *Elfn1* expression in a subpopulation of RGCs beginning with P3 and through adult age, while IIF reveals *Elfn1* positive cell bodies in the GCL and a narrowly stratified band in adult but not P7 IPL. Both the intensely labelled GCL cell bodies and the *Elfn1* positive IPL sublamina are under *Brn3a* control, as they are absent from the *Brn3a* KO retina. In addition, immuno-detection of *Elfn1* protein confirmed the previously described punctate (synaptic) pattern in the OPL [81], but also revealed expression in Photoreceptors, Horizontal, Amacrine and RGCs beginning at P7 and into the adult age. A similar

pattern is revealed by Cao et al. [81] in supplementary material. These results are distinct from the ISH pattern, which confirms widespread retinal expression of *Elfn1* only in the adult. This may be due to distinctions in sensitivity between ISH probe and antibody, or different stability of the mRNA versus protein.

The broad expression of *Ntrk1* (encoding the neurotrophin receptor *TrkA*) in Bipolar, Amacrine and RGCs raises some interesting questions regarding the role of neurotrophic support in the inner retina. Whereas a role of *TrkA* as a RGC receptor for target derived neurotrophins originating in the retinorecipient areas has been proposed [83], the expression in many inner retina neurons after eye opening may suggest a broader role in establishing and maintaining synaptic communication in the IPL.

Pnkd exhibits a significant differential between GCL and INL especially in the adult, when the GCL pattern becomes sparse, while *Rims1* is highly expressed in sparse populations in the adult, combined with lower expression level in the rest of the INL and GCL. *Pnkd* could be implicated in presynaptic vesicle release, by interacting with the protein encoded by *Rims1* [52], a major component of the vesicle release machinery in multiple neuronal types [84, 85]. Thus *Pnkd* and/or *Rims1* could potentially cooperate in modulating the synaptic release properties for distinct RGC subtypes.

Three genes from the secreted proteins group are also associated with synaptic function. *Nptx1* (neuronal pentraxin 1, NP1) is a trans-synaptic factor for glutamate receptor subunit *GluR4* recruitment to synapses, and it is secreted from presynaptic neurons [47]. The product of *Nptx2* gene – *Narp* (neuronal activity regulated protein) is also synaptically released [86], and it is crucial for excitatory synapse maturation in hippocampus [87]. Both *Narp* and *Nptx1* participate in synaptic refinement in developing visual system [88]. In our ISH screen, mRNAs of those two genes are sparsely and highly expressed in both the INL and the GCL, but *Nptx1* seems more GCL-enriched and *Brn3a*-dependent compared to *Nptx2* during postnatal development. *Sez6l2* is a member of the “Brain-Specific Receptor-Like” family of proteins which contains single-pass transmembrane receptors whose extracellular domain can be cleaved [89, 90]. Knock-out mice for the three members of this family exhibit synapse formation abnormalities in the cerebellum, and autoantibodies against *Sez6l2* are implicated in an autoimmune syndrome comprising ataxia and retinopathy [90, 91]. *Sez6l2* seems to maintain a level of enrichment in the GCL from P3 to P14 in our ISH and the related *Sez6l* is expressed in subpopulations of RGCs and Amacrine cells [92].

The final group contains genes encoding cell surface molecules potentially involved in cell-cell communication

and/or axon/dendrite growth. *Cdh4* (R-cadherin) is a cell adhesion molecule which was previously shown to be expressed in the retina in RGCs, Amacrine and Horizontal cells, findings which were largely confirmed in our ISH and IIF data [93–95]. Although our ISH data also shows a modest regulation of *Cdh4* by *Brn3a* at late postnatal ages, the two IPL laminae typically marked by *Cdh4* protein [94] are not affected in *Brn3a* KO mice, suggesting that they are generated by Amacrine cells or *Brn3a* independent RGCs. We also find late developmental GCL enrichment and *Brn3a* regulation for *Pcdh20*, a protocadherin expressed in several other neuronal cell types [96, 97]. In contrast, *Rtn4rl2*, encoding the Nogo receptor 2, is GCL enriched only early (P0-P3), and then gets upregulated in the INL. Its exact function in neuronal development, including the visual system is still unclear [98–100]. Finally, not much is known about the two transmembrane proteins *Tmem25* and *Tmem91*.

Our screen also revealed several molecules that are associated with neuronal activity. Several genes (e.g. *Hpc* and *Rbfox1*) have a peak of expression at P14, with decreasing abundance in the adult. This could represent the changes in almost mature retina after eye-opening, when the amounts of gene and protein expression required for arbor formation and growth are substituted with the amounts needed for maintenance of the structure and functionality.

According to our data, *Brn3a* regulates constitutively expressed partner of the immediate early gene *Nptx2* – *Nptx1* [47, 86, 87, 101, 102], as well as the GABA receptor subunit *Gabra1* [103] around and after eye-opening (P14, P22), when synaptic maturation in retinal circuits occurs [104]. Assuming that this is not caused by specific, late RGC cell loss, it would argue for a role of *Brn3a* in functional maturation of RGCs. Those changes take place during the period of light-driven dendritic refinement, and they are morphologically subtle compared to events during first 2 postnatal weeks [10].

Conclusions

Brn3a controls the expression of several GCL-enriched genes which encode synaptic, cell-surface and intracellular proteins. However, the extent and temporal dynamics of this regulation for molecules within different groups could vary, potentially depending on their molecular roles during specific stages of RGC subtype development (Table 3). The candidates identified by RNA sequencing of purified RGCs at a particular developmental time point have to be assessed using transcript-level analysis and throughout development, in order to identify potential RGC type markers. Most of the studied genes show GCL-enriched pattern of expression, and more than a half of them show *Brn3a* dependency during particular postnatal developmental time points. However, only

Mapk10, Tusc5 and Cdh4 represent a developmentally consistent targets of Brn3a-mediated regulation in the mouse retina. According to Brn3a KO GCL pattern, while Mapk10 and Cdh4 expression are not entirely controlled by Brn3a, Tusc5⁺ cell bodies are almost completely eliminated from Brn3a KO retinas. Tusc5 thus could be a marker of one or a few Brn3a-expressing and -dependent RGC subtypes.

Additional file

Additional file 1: Table S1. Semi-quantitative assessment of the expression of potential Brn3a target genes by ISH densitometry. (ZIP 47 kb)

Abbreviations

AP: Alkaline phosphatase; BAC: Bacterial artificial chromosome; BSA: Bovine serum albumin; ChAT: Choline acetyl transferase; CPM: Counts per million reads; ES cell: Embryonic stem cell; FPKM: Fragments per million reads per gene kilobase; GCL: ganglion cell layer; ILF: Indirect immunofluorescence; INL: Inner nuclear layer; IPL: Inner plexiform layer; ISH: in situ hybridization; NBL: Neuroblast layer; NDS: Normal donkey serum; ONL: Outer nuclear layer; OPL: Outer plexiform layer; PBS: Phosphate buffered saline; PFA: paraformaldehyde; RGC: Retinal ganglion cell; RNASeq: RNA sequencing; RT: Room temperature; RT-PCR: Reverse transcription–polymerase chain reaction; TF: Transcription factor; 3'-UTR: 3'-untranslated region

Acknowledgements

We would like to thank Dr. Kirill Martemyanov from The Scripps Research Institute, Jupiter, USA for providing primary anti-Elfn1 antibody, National Eye Institute IRTA-fellow Nadia Parmhans for the help with animal genotyping and Zbynek Kozmik, Institute of Molecular Genetics of the ASCR, Prague, Czech Republic for Rax:Cre mice.

Funding

The funding was obtained from the NIH Intramural Program. NIH funding body did not have any role in the design of the study and collection, analysis and interpretation of data, and in writing the manuscript.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors contributions

V.M. performed all experiments and participated in planning the experiments and writing the manuscript. M.B. performed RNASeq transcript and gene level expression analysis. T.B. participated in planning the experiments and writing the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All animal procedures were approved by the National Eye Institute (NEI) Animal Care and Use Committee under protocol NEI640.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Retinal Circuit Development & Genetics Unit, Building 6, Room 331B Center Drive, Bethesda, MD 20892–0610, USA. ²Genomics Core, Neurobiology-Neurodegeneration & Repair Laboratory, National Eye Institute, NIH, Building 6, Room 331B Center Drive, Bethesda, MD 20892–0610, USA.

Received: 20 December 2017 Accepted: 6 June 2018

Published online: 29 June 2018

References

- Badea TC, Nathans J. Quantitative analysis of neuronal morphologies in the mouse retina visualized by using a genetically directed reporter. *J Comp Neurol*. 2004;480(4):331–51.
- Badea TC, Nathans J. Morphologies of mouse retinal ganglion cells expressing transcription factors Brn3a, Brn3b, and Brn3c: Analysis of wild type and mutant cells using genetically-directed sparse labeling. *Vision Res*. 2011;51(2):269–79.
- Coombs J, van der List D, Wang G-Y, Chalupa LM. Morphological properties of mouse retinal ganglion cells. *Neuroscience*. 2006;140(1):123–36.
- Sumbul U, Song S, McCulloch K, Becker M, Lin B, Sanes JR, Masland RH, Seung HS. A genetic and computational approach to structurally classify neuronal types. *Nat Commun*. 2014;5:3512.
- Sajgo S, Ghinia MG, Brooks M, Kretschmer F, Chuang K, Hiriyanna S, Wu Z, Popescu O, Badea TC. Molecular codes for cell type specification in Brn3 retinal ganglion cells. *Proc Natl Acad Sci U S A*. 2017;114(20):E3974–83.
- Godement P, Salaun J, Imbert M. Prenatal and postnatal development of retinogeniculate and retinocollicular projections in the mouse. *J Comp Neurol*. 1984;230(4):552–75.
- Marcus RC, Mason CA. The first retinal axon growth in the mouse optic chiasm: axon patterning and the cellular environment. *J Neurosci*. 1995; 15(10):6389–402.
- Coombs JL, Van Der List D, Chalupa LM. Morphological properties of mouse retinal ganglion cells during postnatal development. *J Comp Neurol*. 2007; 503(6):803–14.
- Diao L, Sun W, Deng Q, He S. Development of the mouse retina: emerging morphological diversity of the ganglion cells. *J Neurobiol*. 2004;61(2):236–49. PubMed PMID: 15389605.
- Liu X, Robinson ML, Schreiber AM, Wu V, Lavail MM, Cang J, Copenhagen DR. Regulation of neonatal development of retinal ganglion cell dendrites by neurotrophin-3 overexpression. *J Comp Neurol*. 2009;514(5):449–58.
- Badea TC, Cahill H, Ecker J, Hattar S, Nathans J. Distinct Roles of Transcription Factors Brn3a and Brn3b in Controlling the Development, Morphology, and Function of Retinal Ganglion Cells. *Neuron*. 2009;61(6):852–64.
- Siegert S, Cabuy E, Scherf BG, Kohler H, Panda S, Le YZ, Fehling HJ, Gaidatzis D, Stadler MB, Roska B. Transcriptional code and disease map for adult retinal cell types. *Nat Neurosci*. 2012;15(3):487–95. S481–482
- Wang Q, Marcucci F, Cerullo I, Mason C. Ipsilateral and Contralateral Retinal Ganglion Cells Express Distinct Genes during Decussation at the Optic Chiasm. *eNeuro*. 2016;3(6)
- Xiang M, Zhou L, Macke JP, Yoshioka T, Hendry SH, Eddy RL, Shows TB, Nathans J. The Brn-3 family of POU-domain factors: primary structure, binding specificity, and expression in subsets of retinal ganglion cells and somatosensory neurons. *J Neurosci*. 1995;15(7 Pt 1):4762–85.
- Quina LA, Pak W, Lanier J, Banwait P, Gratwick K, Liu Y, Velasquez T, O'Leary DDM, Goulding M, Turner EE. Brn3a-expressing retinal ganglion cells project specifically to thalamocortical and collicular visual pathways. *J Neurosci*. 2005;25(50):11595–11,604.
- Gan L, Wang SW, Huang Z, Klein WH. POU domain factor Brn-3b is essential for retinal ganglion cell differentiation and survival but not for initial cell fate specification. *Dev Biol*. 1999;210(2):469–80.
- Erkman L, Yates PA, McLaughlin T, McEvilly RJ, Whisenhunt T, O'Connell SM, Krones AI, Kirby MA, Rapaport DH, Birmingham JR, et al. A POU domain transcription factor-dependent program regulates axon pathfinding in the vertebrate visual system. *Neuron*. 2000;28(3):779–92.
- Wang SW, Gan L, Martin SE, Klein WH. Abnormal polarization and axon outgrowth in retinal ganglion cells lacking the POU-domain transcription factor Brn-3b. *Mol Cell Neurosci*. 2000;16(2):141–56.
- Mu X, Beremand PD, Zhao S, Pershad R, Sun H, Scarpa A, Liang S, Thomas TL, Klein WH. Discrete gene sets depend on POU domain transcription factor Brn3b/Brn-3.2/POU4f2 for their expression in the mouse embryonic retina. *Development*. 2004;131(6):1197–210.
- Qiu F, Jiang H, Xiang M. A comprehensive negative regulatory program controlled by Brn3b to ensure ganglion cell specification from multipotential retinal precursors. *J Neurosci*. 2008;28(13): 3392–403.

21. Mu X, Fu X, Beremand PD, Thomas TL, Klein WH. Gene regulation logic in retinal ganglion cell development: Isl1 defines a critical branch distinct from but overlapping with Pou4f2. *Proc Natl Acad Sci U S A*. 2008;105(19):6942–7.
22. Elshatory Y, Deng M, Xie X, Gan L. Expression of the LIM-homeodomain protein Isl1 in the developing and mature mouse retina. *J Comp Neurol*. 2007;503(1):182–97.
23. Elshatory Y, Everhart D, Deng M, Xie X, Barlow RB, Gan L. Islet-1 controls the differentiation of retinal bipolar and cholinergic amacrine cells. *J Neurosci*. 2007;27(46):12707–12,720.
24. Liu W, Khare SL, Liang X, Peters MA, Liu X, Cepko CL, Xiang M. All Brn3 genes can promote retinal ganglion cell differentiation in the chick. *Development*. 2000;127(15):3237–47.
25. Pan L, Yang Z, Feng L, Gan L. Functional equivalence of Brn3 POU-domain transcription factors in mouse retinal neurogenesis. *Development*. 2005;132(4):703–12.
26. McEvelly RJ, Erkman L, Luo L, Sawchenko PE, Ryan AF, Rosenfeld MG. Requirement for Brn-3.0 in differentiation and survival of sensory and motor neurons. *Nature*. 1996;384(6609):574–7.
27. Xiang M, Gan L, Zhou L, Klein WH, Nathans J. Targeted deletion of the mouse POU domain gene Brn-3a causes selective loss of neurons in the brainstem and trigeminal ganglion, uncoordinated limb movement, and impaired suckling. *Proc Natl Acad Sci U S A*. 1996;93(21):11950–11,955.
28. Shi M, Kumar SR, Motajo O, Kretschmer F, Mu X, Badaea TC. Genetic interactions between Brn3 transcription factors in retinal ganglion cell type specification. *PLoS one*. 2013;8(10):e76347.
29. Patel T, Hobert O. Coordinated control of terminal differentiation and restriction of cellular plasticity. *Elife*. 2017;6.
30. Guillemot F. Spatial and temporal specification of neural fates by transcription factor codes. *Development*. 2007;134(21):3771–80.
31. Jessell TM. Neuronal specification in the spinal cord: inductive signals and transcriptional codes. *Nat Rev Genet*. 2000;1(1):20–9.
32. Halbleib JM, Nelson WJ. Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. *Genes Dev* 2006, 20(23):3199–3214.
33. Sakurai T. The role of cell adhesion molecules in brain wiring and neuropsychiatric disorders. *Mol Cell Neurosci*. 2017;81:4–11.
34. Hirano S, Takeichi M. Cadherins in brain morphogenesis and wiring. *Physiol Rev*. 2012;92(2):597–634.
35. Chang JD, Field SJ, Rameh LE, Carpenter CL, Cantley LC. Identification and characterization of a phosphoinositide phosphate kinase homolog. *J Biol Chem*. 2004;279(12):11672–11,679.
36. Conde C, Caceres A. Microtubule assembly, organization and dynamics in axons and dendrites. *Nat Rev Neurosci*. 2009;10(5):319–32.
37. Dent EW, Gupton SL, Gertler FB. The growth cone cytoskeleton in axon outgrowth and guidance. *Cold Spring Harb Perspect Biol*. 2011;3(3).
38. Georges PC, Hadzimidichalis NM, Sweet ES, Firestein BL. The yin-yang of dendrite morphology: unity of actin and microtubules. *Mol Neurobiol*. 2008;38(3):270–84.
39. Barnat M, Enslin H, Propst F, Davis RJ, Soares S, Nothias F. Distinct roles of c-Jun N-terminal kinase isoforms in neurite initiation and elongation during axonal regeneration. *J Neurosci*. 2010;30(23):7804–16.
40. Barford K, Deppmann C, Winckler B. The neurotrophin receptor signaling endosome: Where trafficking meets signaling. *Dev Neurobiol*. 2017;77(4):405–18.
41. Huber AB, Kolodkin AL, Ginty DD, Cloutier JF. Signaling at the growth cone: ligand-receptor complexes and the control of axon growth and guidance. *Annu Rev Neurosci*. 2003;26:509–63.
42. Luo L. Rho GTPases in neuronal morphogenesis. *Nat Rev Neurosci*. 2000;1(3):173–80.
43. Villarreal-Campos D, Gastaldi L, Conde C, Caceres A, Gonzalez-Billault C. Rab-mediated trafficking role in neurite formation. *J Neurochem*. 2014;129(2):240–8.
44. Sudhof TC. The presynaptic active zone. *Neuron*. 2012;75(1):11–25.
45. Sudhof TC. Synaptic Neurexin Complexes: A Molecular Code for the Logic of Neural Circuits. *Cell*. 2017;171(4):745–69.
46. Zipursky SL, Sanes JR. Chemoaffinity revisited: dscams, protocadherins, and neural circuit assembly. *Cell*. 2010;143(3):343–53.
47. Sia GM, Beique JC, Rumbaugh G, Cho R, Worley PF, Hagan RL. Interaction of the N-terminal domain of the AMPA receptor GluR4 subunit with the neuronal pentraxin NP1 mediates GluR4 synaptic recruitment. *Neuron*. 2007;55(1):87–102.
48. Schwab ME. Functions of Nogo proteins and their receptors in the nervous system. *Nat Rev Neurosci*. 2010;11(12):799–811.
49. Klimova L, Lachova J, Machon O, Sedlacek R, Kozmik Z. Generation of mRx-Cre transgenic mouse line for efficient conditional gene deletion in early retinal progenitors. *PLoS one*. 2013;8(5):e63029.
50. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Brief Bioinform*. 2013;14(2):178–92.
51. Matsunami H, Takeichi M. Fetal brain subdivisions defined by R- and E-cadherin expressions: evidence for the role of cadherin activity in region-specific, cell-cell adhesion. *Dev Biol*. 1995;172(2):466–78.
52. Shen Y, Ge WP, Li Y, Hirano A, Lee HY, Rohlmann A, Missler M, Tsien RW, Jan LY, Fu YH, et al. Protein mutated in paroxysmal dyskinesia interacts with the active zone protein RIM and suppresses synaptic vesicle exocytosis. *Proc Natl Acad Sci U S A*. 2015;112(10):2935–41.
53. Carlsson P, Mahlapuu M. Forkhead transcription factors: key players in development and metabolism. *Dev Biol*. 2002;250(1):1–23.
54. Pan D, Rubin GM. Targeted expression of teashirt induces ectopic eyes in *Drosophila*. *Proc Natl Acad Sci U S A*. 1998;95(26):15508–15,512.
55. Rousso DL, Qiao M, Kagan RD, Yamagata M, Palmiter RD, Sanes JR. Two Pairs of ON and OFF Retinal Ganglion Cells Are Defined by Intersectional Patterns of Transcription Factor Expression. *Cell Rep*. 2016;15(9):1930–44.
56. Sato C, Iwai-Takekoshi L, Ichikawa Y, Kawasaki H. Cell type-specific expression of FoxP2 in the ferret and mouse retina. *Neurosci Res*. 2017;117:1–13.
57. French CA, Fisher SE. What can mice tell us about Foxp2 function? *Curr Opin Neurobiol*. 2014;28:72–9.
58. Caubit X, Tiveron MC, Cremer H, Fasano L. Expression patterns of the three Teashirt-related genes define specific boundaries in the developing and postnatal mouse forebrain. *J Comp Neurol*. 2005;486(1):76–88.
59. Gehman LT, Stoilov P, Maguire J, Damianov A, Lin CH, Shiue L, Ares M Jr, Mody I, Black DL. The splicing regulator Rbfox1 (A2BP1) controls neuronal excitation in the mammalian brain. *Nat Genet*. 2011;43(7):706–11.
60. Kielar M, Tuy FP, Bizzotto S, Lebrand C, de Juan Romero C, Poirier K, Oegema R, Mancini GM, Bahi-Buisson N, Olaso R, et al. Mutations in Eml1 lead to ectopic progenitors and neuronal heterotopia in mouse and human. *Nat Neurosci*. 2014;17(7):923–33.
61. Korenbrot JI, Mehta M, Tserentsoodol N, Postlethwait JH, Rebrik TI. EML1 (CNG-modulin) controls light sensitivity in darkness and under continuous illumination in zebrafish retinal cone photoreceptors. *J Neurosci*. 2013;33(45):17763–17,776.
62. Rebrik TI, Botchkina I, Arshavsky VY, Craft CM, Korenbrot JI. CNG-modulin: a novel Ca-dependent modulator of ligand sensitivity in cone photoreceptor cGMP-gated ion channels. *J Neurosci*. 2012;32(9):3142–53.
63. Tzingounis AV, Kobayashi M, Takamatsu K, Nicoll RA. Hippocalcin gates the calcium activation of the slow afterhyperpolarization in hippocampal pyramidal cells. *Neuron*. 2007;53(4):487–93.
64. Yang DD, Kuan CY, Whitmarsh AJ, Rincon M, Zheng TS, Davis RJ, Rakic P, Flavell RA. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. *Nature*. 1997;389(6653):865–70.
65. Yu P, Agbaegbu C, Malide DA, Wu X, Katagiri Y, Hammer JA, Geller HM. Cooperative interactions of LPPR family members in membrane localization and alteration of cellular morphology. *J Cell Sci*. 2015;128(17):3210–22.
66. Brauer AU, Nitsch R. Plasticity-related genes (PRGs/LRPs): a brain-specific class of lysophospholipid-modifying proteins. *Biochim Biophys Acta*. 2008;1781(9):595–600.
67. Shi L, Wang K, Zhao M, Yuan X, Huang C. Overexpression of PIP5K1I suppresses the growth of human cervical cancer cells in vitro and in vivo. *Cell Biol Int*. 2010;34(3):309–15.
68. Blankenship AG, Feller MB. Mechanisms underlying spontaneous patterned activity in developing neural circuits. *Nat Rev Neurosci*. 2010;11(1):18–29.
69. Sanes JR, Zipursky SL. Design principles of insect and vertebrate visual systems. *Neuron*. 2010;66(1):15–36.
70. Burana D, Yoshihara H, Tanno H, Yamamoto A, Saeki Y, Tanaka K, Komada M. The Ankr13 Family of Ubiquitin-interacting Motif-bearing Proteins Regulates Valosin-containing Protein/p97 Protein-mediated Lysosomal Trafficking of Caveolin 1. *J Biol Chem*. 2016;291(12):6218–31.
71. Lu W, Ziff EB. PICK1 interacts with ABP/GRIP to regulate AMPA receptor trafficking. *Neuron*. 2005;47(3):407–21.
72. Bushlin I, Petralia RS, Wu F, Harel A, Mughal MR, Mattson MP, Yao PJ. Clathrin assembly protein AP180 and CALM differentially control axogenesis and dendrite outgrowth in embryonic hippocampal neurons. *J Neurosci*. 2008;28(41):10257–10,271.

73. Fazakerley DJ, Naghilo S, Chaudhuri R, Koumanov F, Burchfield JG, Thomas KC, Krycer JR, Prior MJ, Parker BL, Murrow BA, et al. Proteomic Analysis of GLUT4 Storage Vesicles Reveals Tumor Suppressor Candidate 5 (TUSC5) as a Novel Regulator of Insulin Action in Adipocytes. *J Biol Chem*. 2015;290(39):23528–42.
74. Oort PJ, Warden CH, Baumann TK, Knotts TA, Adams SH. Characterization of Tusc5, an adipocyte gene co-expressed in peripheral neurons. *Mol Cell Endocrinol*. 2007;276(1–2):24–35.
75. Kanageswaran N, Demond M, Nagel M, Schreiner BS, Baumgart S, Scholz P, Altmuller J, Becker C, Doerner JF, Conrad H, et al. Deep sequencing of the murine olfactory receptor neuron transcriptome. *PLoS one*. 2015;10(1):e0113170.
76. Quraishi S, Gayet J, Morgans CW, Duvoisin RM. Distribution of group-III metabotropic glutamate receptors in the retina. *J Comp Neurol*. 2007;501(6):931–43.
77. Bleckert A, Parker ED, Kang Y, Pancaroglu R, Soto F, Lewis R, Craig AM, Wong RO. Spatial relationships between GABAergic and glutamatergic synapses on the dendrites of distinct types of mouse retinal ganglion cells across development. *PLoS one*. 2013;8(7):e69612.
78. Haverkamp S, Wassle H. Immunocytochemical analysis of the mouse retina. *J Comp Neurol*. 2000;424(1):1–23.
79. Antflick JE, Hampson DR. Modulation of glutamate release from parallel fibers by mGlu4 and pre-synaptic GABA(A) receptors. *J Neurochem*. 2012;120(4):552–63.
80. Dolan J, Mitchell KJ. Mutation of Elnf1 in mice causes seizures and hyperactivity. *PLoS one*. 2013;8(11):e80491.
81. Cao Y, Sarria I, Fehlhaber KE, Kamasawa N, Orlandi C, James KN, Hazen JL, Gardner MR, Farzan M, Lee A, et al. Mechanism for Selective Synaptic Wiring of Rod Photoreceptors into the Retinal Circuitry and Its Role in Vision. *Neuron*. 2015;87(6):1248–60.
82. Sylwestrak EL, Ghosh A. Elnf1 regulates target-specific release probability at CA1-interneuron synapses. *Science*. 2012;338(6106):536–40.
83. Zanellato A, Comelli MC, Dal Toso R, Carmignoto G. Developing rat retinal ganglion cells express the functional NGF receptor p140trkA. *Dev Biol*. 1993;159(1):105–13.
84. Kaeser PS, Deng L, Wang Y, Dulubova I, Liu X, Rizo J, Sudhof TC. RIM proteins tether Ca²⁺ channels to presynaptic active zones via a direct PDZ-domain interaction. *Cell*. 2011;144(2):282–95.
85. Schoch S, Castillo PE, Jo T, Mukherjee K, Geppert M, Wang Y, Schmitz F, Malenka RC, Sudhof TC. RIM1alpha forms a protein scaffold for regulating neurotransmitter release at the active zone. *Nature*. 2002;415(6869):321–6.
86. Tsui CC, Copeland NG, Gilbert DJ, Jenkins NA, Barnes C, Worley PF. Narp, a novel member of the pentraxin family, promotes neurite outgrowth and is dynamically regulated by neuronal activity. *J Neurosci*. 1996;16(8):2463–78.
87. Pelkey KA, Barksdale E, Craig MT, Yuan X, Sukumaran M, Vargish GA, Mitchell RM, Wyeth MS, Petralia RS, Chittajallu R, et al. Pentraxins coordinate excitatory synapse maturation and circuit integration of parvalbumin interneurons. *Neuron*. 2015;85(6):1257–72.
88. Bjartmar L, Huberman AD, Ullian EM, Renteria RC, Liu X, Xu W, Prezioso J, Susman MW, Stellwagen D, Stokes CC, et al. Neuronal pentraxins mediate synaptic refinement in the developing visual system. *J Neurosci*. 2006;26(23):6269–81.
89. Boonen M, Staudt C, Gilis F, Oorschot V, Klumperman J, Jadot M. Cathepsin D and its newly identified transport receptor SEZ6L2 can modulate neurite outgrowth. *J Cell Sci*. 2016;129(3):557–68.
90. Miyazaki T, Hashimoto K, Uda A, Sakagami H, Nakamura Y, Saito SY, Nishi M, Kume H, Tohgo A, Kaneko I, et al. Disturbance of cerebellar synaptic maturation in mutant mice lacking BSRPs, a novel brain-specific receptor-like protein family. *FEBS Lett*. 2006;580(17):4057–64.
91. Yaguchi H, Yabe I, Takahashi H, Okumura F, Takeuchi A, Horiuchi K, Kano T, Kanda A, Saito W, Matsumoto M, et al. Identification of anti-Sez6l2 antibody in a patient with cerebellar ataxia and retinopathy. *J Neurol*. 2014;261(1):224–6.
92. Gunnersen JM, Kuek A, Phipps JA, Hammond VE, Puthussery T, Fletcher EL, Tan SS. Seizure-related gene 6 (Sez-6) in amacrine cells of the rodent retina and the consequence of gene deletion. *PLoS one*. 2009;4(8):e6546.
93. Duan X, Krishnaswamy A, De la Huerta I, Sanes JR. Type II cadherins guide assembly of a direction-selective retinal circuit. *Cell*. 2014;158(4):793–807.
94. Honjo M, Tanihara H, Suzuki S, Tanaka T, Honda Y, Takeichi M. Differential expression of cadherin adhesion receptors in neural retina of the postnatal mouse. *Invest Ophthalmol Vis Sci*. 2000;41(2):546–51.
95. Inuzuka H, Miyatani S, Takeichi M. R-cadherin: a novel Ca²⁺-dependent cell-cell adhesion molecule expressed in the retina. *Neuron*. 1991;7(1):69–79.
96. Kim SY, Mo JW, Han S, Choi SY, Han SB, Moon BH, Rhyu IJ, Sun W, Kim H. The expression of non-clustered protocadherins in adult rat hippocampal formation and the connecting brain regions. *Neuroscience*. 2010;170(1):189–99.
97. Lee W, Cheng TW, Gong Q. Olfactory sensory neuron-specific and sexually dimorphic expression of protocadherin 20. *J Comp Neurol*. 2008;507(1):1076–86.
98. Wills ZP, Mandel-Brehm C, Mardinly AR, McCord AE, Giger RJ, Greenberg ME. The nogo receptor family restricts synapse number in the developing hippocampus. *Neuron*. 2012;73(3):466–81.
99. Baumer BE, Kurz A, Borrie SC, Sickinger YA, Dours-Zimmermann MT, Zimmermann DR, Bandtlow CE. Nogo receptor homolog NgR2 expressed in sensory DRG neurons controls epidermal innervation by interaction with Versican. *J Neurosci*. 2014;34(5):1633–46.
100. Dickendesher TL, Baldwin KT, Mironova YA, Koriyama Y, Raiker SJ, Askew KL, Wood A, Geoffroy CG, Zheng B, Liepmann CD, et al. NgR1 and NgR3 are receptors for chondroitin sulfate proteoglycans. *Nat Neurosci*. 2012;15(5):703–12.
101. O'Brien RJ, Xu D, Petralia RS, Steward O, Hugarin RL, Worley P. Synaptic clustering of AMPA receptors by the extracellular immediate-early gene product Narp. *Neuron*. 1999;23(2):309–23.
102. Xu D, Hopf C, Reddy R, Cho RW, Guo L, Lanahan A, Petralia RS, Wenthold RJ, O'Brien RJ, Worley P. Narp and NP1 form heterocomplexes that function in developmental and activity-dependent synaptic plasticity. *Neuron*. 2003;39(3):513–28.
103. Ponomarev I, Maiya R, Harnett MT, Schafer GL, Ryabinin AE, Blednov YA, Morikawa H, Boehm SL 2nd, Homanics GE, Berman AE, et al. Transcriptional signatures of cellular plasticity in mice lacking the alpha1 subunit of GABAA receptors. *J Neurosci*. 2006;26(21):5673–83.
104. Tian N. Synaptic activity, visual experience and the maturation of retinal synaptic circuitry. *J Physiol*. 2008;586(18):4347–55.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://www.biomedcentral.com/submissions)

